aspirin has been researched along with Graft Occlusion, Vascular in 311 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Graft Occlusion, Vascular: Obstruction of flow in biological or prosthetic vascular grafts.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET) study is a multi-center double-blind randomized controlled trial enrolling patients who have undergone multi-vessel CABG with at least one saphenous vein graft." | 9.27 | Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909). ( Abreu, AM; Boronat, V; Kouchoukos, NT; Kulik, A; Ruel, M, 2018) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 9.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "Aspirin is the most commonly used antiplatelet agent in patients with coronary artery disease (CAD)." | 7.78 | Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist. ( Das, P; Lieberman, P; Pattanaik, D, 2012) |
| "AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)." | 7.77 | Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011) |
| "Between September 1999 and April 2002, a total of 1,236 patients hospitalized for acute coronary syndrome (ACS) were questioned in order to determine whether aspirin intake had been interrupted." | 7.73 | Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. ( Benhamou, M; Cerboni, P; Ferrari, E; Marcel, B, 2005) |
| "The combination of aspirin and dipyridamole is currently used to prevent intimal hyperplasia and to improve long-term vein graft patency following myocardial revascularization." | 7.67 | Comparison of cod-liver oil and aspirin-dipyridamole for the prevention of intimal hyperplasia in autologous vein grafts. ( Cameron, C; Landymore, RW; MacAulay, M; Sheridan, B, 1986) |
| " Conditions characterized by a reduction in platelet survival and where dipyridamole has been used include heart valve replacement, arterial grafting, cerebrovascular disorders, and disorders of peripheral circulation." | 6.15 | Dipyridamole: a critical evaluation. ( Alexander, MR; Rivey, MP; Taylor, JW, 1984) |
| "Aspirin has been convincingly shown to reduce stroke and death in men with transient ischemic attacks (it may possibly be beneficial to women also), myocardial infarction and death in patients with unstable angina, thromboembolic complications associated with artificial heart valves in patients receiving oral anticoagulants (although gastrointestinal bleeding is prohibitive with this combination), and thrombotic occlusion of silicone rubber arteriovenous cannulae in uremic patients undergoing hemodialysis." | 6.15 | Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. ( Harker, LA, 1986) |
| "However, systemic study of thrombus formation in vein grafts is still lacking, and few effective techniques are available to prevent this event." | 5.32 | Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection. ( Hu, Y; Mayr, U; Thompson, WD; Torsney, E; Xu, Q; Zou, Y, 2004) |
| "The Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET) study is a multi-center double-blind randomized controlled trial enrolling patients who have undergone multi-vessel CABG with at least one saphenous vein graft." | 5.27 | Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909). ( Abreu, AM; Boronat, V; Kouchoukos, NT; Kulik, A; Ruel, M, 2018) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 5.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "To compare the risks of vein graft failure and bleeding associated with ticagrelor dual antiplatelet therapy (DAPT) or ticagrelor monotherapy vs aspirin among patients undergoing coronary artery bypass graft surgery." | 5.22 | Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-analysis. ( Angiolillo, DJ; Audisio, K; Fremes, SE; Gaudino, M; Janssen, PWA; Kulik, A; Mehran, R; Peper, J; Redfors, B; Ruel, M; Sandner, S; Saw, J; Soletti, GJ; Starovoytov, A; Ten Berg, JM; Willemsen, LM; Zhao, Q; Zhu, Y, 2022) |
| "The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme." | 4.90 | Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. ( Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S, 2014) |
| "Despite well-documented efficacy, recurrent thrombotic event occurrences, particularly stent thrombosis, have been repeatedly demonstrated in stented patients treated with aspirin and clopidogrel." | 4.90 | Resistance to antiplatelet drugs: what progress has been made? ( Bliden, KP; Gesheff, M; Gurbel, PA; Liu, F; Tantry, US, 2014) |
| " Monotherapy with either aspirin or clopidogrel, reduces the rate of stroke, myocardial infarction, and cardiovascular death in patients suffering from peripheral arterial disease." | 4.85 | Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? ( Milani, RV, 2009) |
| "Aspirin is the most commonly used antiplatelet agent in patients with coronary artery disease (CAD)." | 3.78 | Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist. ( Das, P; Lieberman, P; Pattanaik, D, 2012) |
| "AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)." | 3.77 | Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011) |
| "To study the prevention of occlusion of aortocoronary-artery bypass grafts, we conducted a prospective, randomized, double-blind trial comparing long-term administration of dipyridamole (begun 2 days before operation) plus aspirin (begun 7 hr after operation) with placebo in 407 patients." | 3.76 | Role of platelets and platelet inhibitors in aortocoronary artery vein-graft disease. ( Chesebro, JH; Fuster, V, 1986) |
| "Premature discontinuation of antiplatelet therapy has been identified as a major risk factor for stent thrombosis and prior aspirin withdrawal has been associated with poor prognosis after acute coronary syndrome." | 3.75 | Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. ( Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Faille, D; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009) |
| "Between September 1999 and April 2002, a total of 1,236 patients hospitalized for acute coronary syndrome (ACS) were questioned in order to determine whether aspirin intake had been interrupted." | 3.73 | Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. ( Benhamou, M; Cerboni, P; Ferrari, E; Marcel, B, 2005) |
| "Aspirin was not a significant factor in preventing graft failure or vascular death in patients undergoing bypass for critical limb ischemia." | 3.72 | The efficacy of aspirin in patients undergoing infra-inguinal bypass and identification of high risk patients. ( Edwards, AT; Mahmood, A; Simms, MH; Sintler, M; Smith, SR; Vohra, RK, 2003) |
| "Aspirin is frequently used after vascular reconstruction to pharmacologically prevent graft occlusion and to suppress the development of myointimal hyperplasia in vascular surgery, but its efficacy is controversial." | 3.69 | Aspirin enhances platelet-derived growth factor-induced vascular smooth muscle cell proliferation. ( Bredenberg, CE; Couper, L; Harvey, R; Himmelfarb, J, 1997) |
| "The purpose of this study was to evaluate the efficacy of three drugs (cilazapril, cyclosporine, and aspirin) in modulating the progression of intimal hyperplasia during short postoperative times in short-segment, autogenous vein bypass grafts in a canine model." | 3.68 | Pharmacologic modulation of intimal hyperplasia in canine vein interposition grafts. ( Evancho, MM; Hirko, MK; McShannic, JR; Schmidt, SP; Sharp, WV; Siebert, JD; Sims, RL, 1993) |
| "The combination of aspirin and dipyridamole is currently used to prevent intimal hyperplasia and to improve long-term vein graft patency following myocardial revascularization." | 3.67 | Comparison of cod-liver oil and aspirin-dipyridamole for the prevention of intimal hyperplasia in autologous vein grafts. ( Cameron, C; Landymore, RW; MacAulay, M; Sheridan, B, 1986) |
| "Aspirin was started within 12 h, and study medication within 72 h after CABG." | 2.82 | Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery. ( Bernstein, V; Cairns, J; Mancini, GB; Mayo, J; Saw, J; Skarsgard, P; Starovoytov, A; Wong, GC; Ye, J, 2016) |
| "Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for ≥ 3 months or up to 12 months after implantation." | 2.79 | Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. ( Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W, 2014) |
| "Treatment with dipyridamole plus aspirin had a significant but modest effect in reducing the risk of stenosis and improving the duration of primary unassisted patency of newly created grafts." | 2.74 | Effect of dipyridamole plus aspirin on hemodialysis graft patency. ( Allon, M; Beck, GJ; Braden, GL; Cotton, JR; Davidson, IJ; Delmez, JA; Dember, LM; Dixon, BS; Feldman, HI; Fenves, AZ; Gassman, JJ; Greenberg, A; Greene, T; Himmelfarb, J; Hu, B; Ikizler, TA; Kaufman, JS; Kusek, JW; Lawson, JH; Martin, KJ; McNeil, JW; Meyers, CM; Radeva, MK; Rahman, A; Vazquez, MA; Whiting, JF, 2009) |
| "Reactive thrombocytosis has been reported in 20% of patients after coronary artery bypass grafting (CABG), a frequency that might be related to the high incidence of thrombotic complications." | 2.73 | The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation. ( Alper, AT; Ates, M; Demirtas, MM; Gunay, R; Idiz, M; Kayacioglu, I; Saskin, H; Sensoz, Y; Tangurek, B; Yekeler, I, 2008) |
| "Aspirin resistance was defined as ARU > 550, whereas clopidogrel resistance was defined as percentage platelet inhibition < 40%." | 2.73 | Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. ( Flaherty, CA; Lee, VH; Lopes, DK; Prabhakaran, S; Wells, KR, 2008) |
| "Probucol is a lipid-lowering drug that has an antioxidant effect." | 2.70 | Effect of antioxidant probucol for preventing stent restenosis. ( Cha, KS; Han, JY; Kim, HJ; Kim, JS; Kim, MH, 2002) |
| "Aspirin was better for the prevention of non-venous graft occlusion, and was associated with fewer bleeding episodes." | 2.69 | Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. ( , 2000) |
| "5 microCi is safe and feasible." | 2.69 | beta-Particle-emitting radioactive stent implantation. A safety and feasibility study. ( Coen, VL; den Boer, A; Gijzel, AL; Kay, IP; Levendag, PC; Ligthart, JM; Sabaté, M; Serruys, PW; van Der Giessen, WJ; Wardeh, AJ, 1999) |
| "Aspirin treatment started 24 hours before, and heparin 6 hours and phenprocoumon 2 days after surgery." | 2.67 | Low-dose aspirin versus anticoagulants for prevention of coronary graft occlusion. ( Buchwalsky, R; Fassbender, D; Hahalis, G; Hasford, J; Langbehn, AF; Seggewiss, H; Taillens, C; Theisen, K; Weber, MA; Zitzmann, A, 1990) |
| "Aspirin was initiated either 12 hours before or 6 hours after operation." | 2.67 | Internal mammary artery and saphenous vein graft patency. Effects of aspirin. ( Copeland, J; Goldman, S; Henderson, W; Kern, KB; Khuri, S; Moritz, T; Ovitt, T; Sethi, G; Sharma, GV; Zadina, K, 1990) |
| "The efficacy of aspirin for prevention of thrombotic graft occlusion after coronary artery bypass grafting (CABG) depends both on the dosage and time window of administration." | 2.67 | Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. ( Baron, DW; Gavaghan, TP; Gebski, V, 1991) |
| "Q-wave myocardial infarctions were increased in the aprotinin subgroups (17." | 2.67 | Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. ( Cosgrove, DM; Golding, LA; Heric, B; Loop, FD; Lytle, BW; McCarthy, PM; Novoa, R; Stewart, RW; Taylor, PC, 1992) |
| "Aspirin has an established benefit in reducing the incidence of coronary events and vein graft occlusion." | 2.67 | Pre-operative aspirin decreases platelet aggregation and increases post-operative blood loss--a prospective, randomised, placebo controlled, double-blind clinical trial in 100 patients with chronic stable angina. ( Bevan, DH; Cowans, D; Kallis, P; Talbot, S; Tooze, JA; Treasure, T, 1994) |
| "Indobufen is a possible alternative antiplatelet agent that may be better tolerated." | 2.67 | Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting. ( Beton, D; Campbell, C; Critchley, A; Lawson, RA; Nair, U; Rajah, SM; Rees, M; Saunders, N; Walker, D; Williams, G, 1994) |
| "For this update the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched June 2014) and the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 5)." | 2.52 | Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. ( Acosta, S; Bedenis, R; Lethaby, A; Maxwell, H; Prins, MH, 2015) |
| "It is essential to define/quantify the postoperative blood loss that precludes administration of early aspirin." | 2.50 | Who might benefit from early aspirin after coronary artery surgery? ( Bilkhu, R; Gukop, P; Gutman, N; Karapanagiotidis, GT, 2014) |
| " A low (100 mg) to medium (325 mg) daily aspirin dosage was more effective than a high dose (975 mg)." | 2.38 | Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis. ( Chen, E; Christakis, GT; Fremes, SE; Goldman, BS; Levinton, C; Naylor, CD, 1993) |
| " The bioavailability of plain ASA after oral administration amounts to 40-50% at therapeutic doses." | 2.38 | [Clinical pharmacology of acetylsalicylic acid]. ( Schröder, H; Schrör, K, 1992) |
| "Aspirin resistance was observed in 17 of 109 patients in whom this parameter was measured, and was not significantly associated with VA failure (p = 0." | 1.51 | Effects of aspirin resistance and mean platelet volume on vascular access failure in hemodialysis patients. ( Cho, A; Choi, MJ; Hoon, HC; Koo, JR; Lee, YK; Noh, JW; Yoon, JW, 2019) |
| "Aspirin plays a well-established role in this setting, and for a long time, clopidogrel use has been restricted to patients allergic to aspirin." | 1.51 | Dual platelet antiaggregation therapy after myocardial revascularization surgery. ( Batista, DV; Feitosa, MPM; Lima, EG; Linhares Filho, JPP; Lobo Filho, HG; Serrano Júnior, CV; Soffiatti, CD, 2019) |
| "Aspirin plays a key role in preventing IPS." | 1.42 | In-Pipeline Stenosis: Incidence, Predictors, and Clinical Outcomes. ( Barros, G; Chalouhi, N; Daou, B; Gonzalez, LF; Hasan, D; Jabbour, P; Judy, B; Kung, D; Polifka, A; Rosenwasser, RH; Starke, RM; Tjoumakaris, S, 2015) |
| "Eicosapentaenoic acid (EPA) has been widely accepted to have antiatherosclerotic effects." | 1.40 | Effects of eicosapentaenoic acid on platelet function in patients taking long-term aspirin following coronary stent implantation. ( Hosogoe, N; Ishikawa, S; Isshiki, T; Takada, K; Yokoyama, N, 2014) |
| "Aspirin effect was assessed using the VerifyNow Aspirin Assay, and the effect of clopidogrel was assessed using the VerifyNow P2Y12 Assay and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P)." | 1.35 | Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. ( Beauzile, P; Bonello, L; Gavini, R; Gurbel, P; Kaneshige, K; Kent, K; Pichard, AD; Pinto Slottow, TL; Satler, LF; Scheinowitz, M; Suddath, WO; Sushinsky, SJ; Tantry, U; Torguson, R; Waksman, R; Xue, Z, 2009) |
| "Aspirin use was determined at baseline and one year later." | 1.35 | Consistent aspirin use associated with improved arteriovenous fistula survival among incident hemodialysis patients in the dialysis outcomes and practice patterns study. ( Akizawa, T; Bragg-Gresham, JL; Elder, SJ; Fukuhara, S; Hasegawa, T; Hugh, RC; Jadoul, M; Pisoni, RL; Port, FK; Yamazaki, S, 2008) |
| "Aspirin plays a key role in the secondary prevention of atherothrombotic events and thrombotic complications after stent implantation." | 1.35 | Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. ( Angiolillo, DJ; Bass, TA; Gavazzi, A; Invernizzi, P; Mihalcsik, L; Musumeci, G; Rossini, R; Scuri, P, 2008) |
| "Aspirin has been indicated to maintain venous graft patency in the post-operative period." | 1.33 | Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance. ( Ayaz, S; Balbay, Y; Caldir, V; Guray, U; Guray, Y; Korkmaz, S; Yilmaz, MB, 2005) |
| "However, systemic study of thrombus formation in vein grafts is still lacking, and few effective techniques are available to prevent this event." | 1.32 | Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection. ( Hu, Y; Mayr, U; Thompson, WD; Torsney, E; Xu, Q; Zou, Y, 2004) |
| "Previous myocardial infarction was found in 70 patients (28%)." | 1.32 | National survey of coronary artery bypass grafting for coronary stenosis caused by Kawasaki disease in Japan. ( Kitamura, S; Tsuda, E, 2004) |
| "Aspirin therapy was associated with better secondary graft patency (RR, 0." | 1.31 | Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). ( Dykstra, DM; Gillespie, B; Held, PJ; Saran, R; Wolfe, RA; Young, EW, 2002) |
| " We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk." | 1.31 | Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. ( Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS, 2001) |
| "to investigate the effect of clopidogrel combined with aspirin or aspirin alone on fibromyointimal hyperplasia (FIMH) in a bypass model with native vein grafts (NVG) and biocompound grafts (BCG)." | 1.31 | Prevention of venous graft sclerosis with clopidogrel and aspirin combined with a mesh tubing in a dog model of arteriovenous bypass grafting. ( Gutersohn, A; Hetzer, R; Mülling, C; Musci, M; Sänger, S; Schaffner, T; Wellnhofer, E; Zurbrügg, HR, 2001) |
| "Both everolimus treatment groups significantly reduced in-stent neointimal growth (46% reduction and 42% reduction in intimal thickness in groups 1 and 2, respectively)." | 1.31 | Oral everolimus inhibits in-stent neointimal growth. ( Acampado, E; Farb, A; John, M; Kolodgie, FD; Prescott, MF; Virmani, R, 2002) |
| "Indications for surgery included vertebrobasilar insufficiency (22." | 1.30 | Carotid-subclavian bypass for subclavian artery revascularization: long-term follow-up and effect of antiplatelet therapy. ( Dresler, C; Haverich, A; Wahlers, T; Wittwer, T, 1998) |
| "Aspirin was discontinued on the personal decision of individual physicians." | 1.30 | Reduced frequency of occlusion of aorto-pulmonary shunts in infants receiving aspirin. ( Bürsch, J; Motz, R; Ruschewski, W; Wessel, A, 1999) |
| "Aspirin was sometimes omitted without clear indications." | 1.29 | Omission of aspirin in patients following coronary artery bypass graft surgery. ( Galea, J; Goiti, JJ; Locke, TJ; Manché, A; Smith, GH; Wilkinson, GA, 1994) |
| "The composition of the thrombus is analyzed by double isotope labeling of platelets and fibrinogen." | 1.28 | [Arterioarterial shunt coated with collagen. A model of acute arterial thrombosis for testing antithrombotic agents in rats]. ( Cazenave, JP; Freund, M; Mantz, F, 1991) |
| "Thus aspirin is a potent agent in preventing rethrombosis after thrombolytic recanalization of prosthetic grafts." | 1.27 | Beneficial effect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator. ( Bush, HL; Curl, GR; Deykin, D; Jakubowski, JA, 1986) |
| " Possible explanations for these negative findings include inadequate dosage or form of omega-3 fatty acids and the antiplatelet drugs administered, excessive variability in graft response due to uncharacterized immunologic histocompatibility, and the possible influence of non-platelet-mediated mechanisms." | 1.27 | Effects of aspirin, dipyridamole, and cod liver oil on accelerated myointimal proliferation in canine veno-arterial allografts. ( DeCampli, WM; Handen, CE; Kosek, JC; Miller, DC; Mitchell, RS, 1988) |
| "Graft success was evaluated by patency, thrombus-free surface area, area endothelialized, and graft production of prostacyclin." | 1.27 | Effects of antiplatelet agents in combination with endothelial cell seeding on small-diameter Dacron vascular graft performance in the canine carotid artery model. ( Evancho, MM; Falkow, LJ; Hunter, TJ; Schmidt, SP; Sharp, WV, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 56 (18.01) | 18.7374 |
| 1990's | 84 (27.01) | 18.2507 |
| 2000's | 76 (24.44) | 29.6817 |
| 2010's | 73 (23.47) | 24.3611 |
| 2020's | 22 (7.07) | 2.80 |
| Authors | Studies |
|---|---|
| Kulik, A | 4 |
| Abreu, AM | 3 |
| Boronat, V | 3 |
| Kouchoukos, NT | 3 |
| Ruel, M | 4 |
| Hays, NM | 1 |
| Balsam, LB | 1 |
| Tasaki, D | 1 |
| Arai, H | 1 |
| Yokoyama, K | 1 |
| Yoshizaki, T | 1 |
| Xiang, F | 1 |
| Lin, Y | 1 |
| Chen, B | 1 |
| Sandner, S | 3 |
| Redfors, B | 6 |
| Angiolillo, DJ | 3 |
| Audisio, K | 1 |
| Fremes, SE | 3 |
| Janssen, PWA | 3 |
| Mehran, R | 4 |
| Peper, J | 2 |
| Saw, J | 2 |
| Soletti, GJ | 1 |
| Starovoytov, A | 2 |
| Ten Berg, JM | 5 |
| Willemsen, LM | 3 |
| Zhao, Q | 2 |
| Zhu, Y | 2 |
| Gaudino, M | 3 |
| Guida, GA | 1 |
| Angelini, GD | 3 |
| Zeng, BY | 2 |
| Tseng, PT | 2 |
| Liang, CS | 2 |
| Han, Z | 1 |
| Zhang, G | 1 |
| Chen, Y | 1 |
| Hesterberg, K | 1 |
| Rawal, A | 1 |
| Khan, S | 1 |
| Rashid, A | 1 |
| Jones, D | 1 |
| Siddiqui, T | 1 |
| Khader, TA | 1 |
| Nayyar, M | 1 |
| Shah, R | 1 |
| Cho, S | 1 |
| Kim, JS | 3 |
| Kang, TS | 1 |
| Hong, SJ | 1 |
| Shin, DH | 2 |
| Ahn, CM | 2 |
| Kim, BK | 3 |
| Ko, YG | 2 |
| Choi, D | 2 |
| Song, YB | 1 |
| Hahn, JY | 1 |
| Choi, SH | 1 |
| Gwon, HC | 1 |
| Hong, MK | 4 |
| Jang, Y | 4 |
| Hackeng, CM | 4 |
| Kelder, JC | 3 |
| Tijssen, JGP | 2 |
| van Straten, AHM | 2 |
| Soliman-Hamad, MA | 2 |
| Deneer, VHM | 2 |
| Daeter, EJ | 2 |
| Sonker, U | 2 |
| Klein, P | 2 |
| Faggioni, M | 1 |
| Crowley, A | 1 |
| Claessen, BE | 1 |
| Farhan, S | 1 |
| Mastoris, I | 1 |
| Witzenbichler, B | 3 |
| Maehara, A | 3 |
| Weisz, G | 3 |
| Généreux, P | 4 |
| Ben-Yehuda, O | 2 |
| Kirtane, AJ | 4 |
| Stone, GW | 4 |
| Dickson, SD | 1 |
| Taleb, A | 1 |
| Wiernek, S | 1 |
| Govea, A | 1 |
| Penny, W | 1 |
| Baldetti, L | 1 |
| Melillo, F | 1 |
| Moroni, F | 1 |
| Gallone, G | 1 |
| Pagnesi, M | 1 |
| Venuti, A | 1 |
| Beneduce, A | 1 |
| Calvo, F | 1 |
| Gramegna, M | 1 |
| Godino, C | 1 |
| D'Ascenzo, F | 1 |
| De Ferrari, GM | 1 |
| Capodanno, D | 1 |
| Cappelletti, AM | 1 |
| Zhu, J | 2 |
| Zhang, M | 1 |
| Xue, Q | 1 |
| Hu, J | 1 |
| Liu, H | 2 |
| Wang, R | 1 |
| Wang, X | 2 |
| Bekker, MWA | 1 |
| von Birgelen, C | 1 |
| Brouwer, MA | 2 |
| van der Harst, P | 1 |
| Vlot, EA | 1 |
| Chan Pin Yin, DRPP | 1 |
| Gimbel, ME | 1 |
| Beukema, KF | 1 |
| Rensing, BJWM | 1 |
| van Es, HW | 1 |
| Swaans, MJ | 1 |
| Kitano, D | 1 |
| Migita, S | 1 |
| Li, Y | 1 |
| Takahashi, R | 1 |
| Taniguchi, Y | 1 |
| Kurosawa, T | 1 |
| Sudo, M | 1 |
| Haruta, H | 1 |
| Hiro, T | 1 |
| Takayama, T | 2 |
| Mitsumata, M | 1 |
| Matsumoto, T | 1 |
| Okumura, Y | 1 |
| Hirayama, A | 1 |
| Sinnaeve, PR | 1 |
| Adriaenssens, T | 1 |
| Cannon, CP | 3 |
| Sheriff, F | 1 |
| Inam, ME | 1 |
| Thanh Truong, VT | 1 |
| Lopez-Rivera, V | 1 |
| Lekka, E | 1 |
| Kermali, K | 1 |
| Sheth, S | 1 |
| Maud, A | 1 |
| Gupta, V | 1 |
| Rodriguez, G | 1 |
| Pedroza, C | 1 |
| Chen, PR | 1 |
| Fuertes Ferre, G | 1 |
| Laita Monreal, S | 1 |
| Ortas Nadal, MDR | 1 |
| Sánchez Insa, E | 1 |
| Sánchez Rubio-Lezcano, J | 1 |
| Galache Osuna, JG | 1 |
| Li, R | 1 |
| Lan, B | 1 |
| Zhu, T | 1 |
| Yang, Y | 1 |
| Cai, M | 1 |
| Fang, Z | 1 |
| Ma, C | 1 |
| Chen, S | 1 |
| Im, E | 1 |
| Cho, YH | 2 |
| Suh, Y | 1 |
| Cho, DK | 1 |
| Her, AY | 1 |
| Kim, YH | 2 |
| Lee, K | 1 |
| Kang, WC | 1 |
| Yun, KH | 1 |
| Yoo, SY | 1 |
| Cheong, SS | 1 |
| Lin, SH | 1 |
| Furer, A | 1 |
| Stuckey, TD | 2 |
| Giustino, G | 1 |
| Rinaldi, MJ | 2 |
| Neumann, FJ | 5 |
| Metzger, DC | 2 |
| Henry, TD | 1 |
| Cox, DA | 1 |
| Duffy, PL | 1 |
| Mazzaferri, EL | 1 |
| Ayele, GM | 1 |
| Mintz, GS | 1 |
| Khan, SU | 1 |
| Talluri, S | 1 |
| Rahman, H | 1 |
| Lekkala, M | 1 |
| Khan, MS | 1 |
| Riaz, H | 1 |
| Shah, H | 1 |
| Kaluski, E | 1 |
| Sattur, S | 1 |
| Cho, A | 1 |
| Choi, MJ | 1 |
| Lee, YK | 1 |
| Hoon, HC | 1 |
| Koo, JR | 1 |
| Yoon, JW | 1 |
| Noh, JW | 1 |
| Essbaiheen, F | 1 |
| AlQahtani, H | 1 |
| Almansoori, TM | 1 |
| Cora, EA | 1 |
| Patro, S | 1 |
| Tsehmaister-Abitbul, V | 1 |
| Drake, B | 1 |
| Lesiuk, H | 1 |
| Finitsis, SN | 1 |
| Iancu, D | 1 |
| Fan, PY | 1 |
| Lee, CC | 1 |
| Liu, SH | 1 |
| Li, IJ | 1 |
| Weng, CH | 1 |
| Tu, KH | 1 |
| Hsieh, MY | 1 |
| Kuo, CF | 1 |
| Chang, TY | 1 |
| Tian, YC | 1 |
| Yang, CW | 1 |
| Wu, HH | 1 |
| Gohs, FX | 1 |
| Brodie, BR | 1 |
| McAndrew, T | 1 |
| Lamy, A | 2 |
| Eikelboom, J | 1 |
| Sheth, T | 2 |
| Connolly, S | 2 |
| Bosch, J | 1 |
| Fox, KAA | 1 |
| Lonn, E | 1 |
| Dagenais, G | 1 |
| Widimsky, P | 1 |
| Branch, KRH | 1 |
| Bhatt, DL | 2 |
| Zheng, Z | 2 |
| Straka, Z | 1 |
| Dagenais, F | 1 |
| Kong, Y | 1 |
| Marsden, T | 1 |
| Lee, SF | 1 |
| Copland, I | 1 |
| Yusuf, S | 2 |
| Alexander, JH | 1 |
| Feitosa, MPM | 1 |
| Soffiatti, CD | 1 |
| Linhares Filho, JPP | 1 |
| Batista, DV | 1 |
| Lobo Filho, HG | 1 |
| Lima, EG | 1 |
| Serrano Júnior, CV | 1 |
| Ooi, YK | 1 |
| Ligon, RA | 1 |
| Kelleman, M | 1 |
| Vincent, RN | 1 |
| Bauser-Heaton, HD | 1 |
| Kim, DW | 1 |
| Petit, CJ | 1 |
| Deo, SV | 2 |
| Dunlay, SM | 2 |
| Shah, IK | 1 |
| Altarabsheh, SE | 1 |
| Erwin, PJ | 1 |
| Boilson, BA | 1 |
| Park, SJ | 3 |
| Joyce, LD | 1 |
| Gassman, AA | 1 |
| Degner, BC | 1 |
| Al-Nouri, O | 1 |
| Philippi, L | 1 |
| Hershberger, R | 1 |
| Halandras, P | 1 |
| Aulivola, B | 1 |
| Milner, R | 1 |
| Seckeler, MD | 1 |
| D'Souza, MD | 1 |
| Gangemi, JJ | 1 |
| Hoyer, AW | 1 |
| Jayakumar, KA | 1 |
| Nocerino, AG | 1 |
| Achenbach, S | 1 |
| Taylor, AJ | 1 |
| Nee, R | 1 |
| Parker, AL | 1 |
| Little, DJ | 1 |
| Yuan, CM | 1 |
| Himmelfarb, J | 6 |
| Lowe, SR | 1 |
| Abbott, KC | 1 |
| Silber, S | 1 |
| Belardi, JA | 1 |
| Liu, M | 2 |
| Brar, S | 1 |
| Rothman, M | 1 |
| Windecker, S | 2 |
| Camenzind, E | 1 |
| Boersma, E | 1 |
| Wijns, W | 1 |
| Mauri, L | 1 |
| Rademaker-Havinga, T | 1 |
| Ordoubadi, FF | 1 |
| Suttorp, MJ | 1 |
| Al Kurdi, M | 1 |
| Steg, PG | 2 |
| Takada, K | 1 |
| Ishikawa, S | 1 |
| Yokoyama, N | 1 |
| Hosogoe, N | 1 |
| Isshiki, T | 1 |
| Gukop, P | 1 |
| Gutman, N | 1 |
| Bilkhu, R | 1 |
| Karapanagiotidis, GT | 1 |
| Parekh, P | 1 |
| Agrawal, N | 1 |
| Vasavada, A | 1 |
| Vinchurkar, M | 1 |
| Tantry, US | 1 |
| Gesheff, M | 1 |
| Liu, F | 1 |
| Bliden, KP | 1 |
| Gurbel, PA | 1 |
| Timmers, L | 1 |
| Stella, PR | 1 |
| Agostoni, P | 1 |
| Christ, G | 1 |
| Siller-Matula, JM | 1 |
| Francesconi, M | 1 |
| Dechant, C | 1 |
| Grohs, K | 1 |
| Podczeck-Schweighofer, A | 1 |
| Wu, H | 1 |
| Wang, J | 1 |
| Sun, H | 1 |
| Lv, B | 1 |
| Hu, X | 1 |
| Ma, W | 1 |
| Zhang, J | 1 |
| Ferraris, VA | 1 |
| Bolanos, MD | 1 |
| Lawrie, GM | 1 |
| Bedenis, R | 1 |
| Lethaby, A | 1 |
| Maxwell, H | 1 |
| Acosta, S | 1 |
| Prins, MH | 1 |
| Jim, MH | 1 |
| Wong, KL | 1 |
| Yiu, KH | 1 |
| Liu, C | 1 |
| Chen, D | 1 |
| Jiang, Q | 1 |
| Lu, J | 2 |
| Zuo, L | 1 |
| Tara, S | 1 |
| Kurobe, H | 1 |
| de Dios Ruiz Rosado, J | 1 |
| Best, CA | 1 |
| Shoji, T | 1 |
| Mahler, N | 1 |
| Yi, T | 1 |
| Lee, YU | 1 |
| Sugiura, T | 1 |
| Hibino, N | 1 |
| Partida-Sanchez, S | 1 |
| Breuer, CK | 1 |
| Shinoka, T | 1 |
| Chalouhi, N | 1 |
| Polifka, A | 1 |
| Daou, B | 1 |
| Kung, D | 1 |
| Barros, G | 1 |
| Tjoumakaris, S | 1 |
| Gonzalez, LF | 1 |
| Starke, RM | 1 |
| Hasan, D | 1 |
| Judy, B | 1 |
| Rosenwasser, RH | 1 |
| Jabbour, P | 1 |
| Viecelli, AK | 2 |
| Pascoe, EM | 2 |
| Polkinghorne, KR | 2 |
| Hawley, CM | 2 |
| Paul-Brent, PA | 2 |
| Badve, SV | 2 |
| Cass, A | 2 |
| Johnson, DW | 1 |
| Kerr, PG | 2 |
| Mori, TA | 2 |
| Scaria, A | 1 |
| Hooi, SL | 1 |
| Ong, ML | 1 |
| Irish, AB | 2 |
| Briasoulis, A | 1 |
| Palla, M | 1 |
| Wong, GC | 1 |
| Mayo, J | 1 |
| Bernstein, V | 1 |
| Mancini, GB | 1 |
| Ye, J | 1 |
| Skarsgard, P | 1 |
| Cairns, J | 1 |
| Gargiulo, G | 1 |
| Costa, F | 1 |
| Ariotti, S | 1 |
| Biscaglia, S | 1 |
| Campo, G | 1 |
| Esposito, G | 1 |
| Leonardi, S | 1 |
| Vranckx, P | 1 |
| Valgimigli, M | 2 |
| Shimada, YJ | 1 |
| Bansilal, S | 1 |
| Wiviott, SD | 1 |
| Becker, RC | 1 |
| Harrington, RA | 1 |
| Himmelmann, A | 1 |
| Neely, B | 1 |
| Husted, S | 1 |
| James, SK | 1 |
| Katus, HA | 1 |
| Lopes, RD | 1 |
| Storey, RF | 2 |
| Wallentin, L | 1 |
| Camaro, C | 1 |
| Damen, SA | 1 |
| Kedhi, E | 1 |
| Lee, SW | 3 |
| Verdoia, M | 1 |
| Barbieri, L | 1 |
| Rognoni, A | 1 |
| van T Hof, AW | 1 |
| Ligtenberg, E | 1 |
| de Boer, MJ | 1 |
| Suryapranata, H | 1 |
| De Luca, G | 1 |
| Zhang, JJ | 1 |
| Gao, XF | 1 |
| Ge, Z | 1 |
| Tian, NL | 1 |
| Liu, ZZ | 1 |
| Lin, S | 1 |
| Ye, F | 1 |
| Chen, SL | 1 |
| Hooi, LS | 1 |
| Voss, D | 1 |
| Ong, LM | 1 |
| Palmerini, T | 2 |
| Della Riva, D | 1 |
| Benedetto, U | 1 |
| Bacchi Reggiani, L | 1 |
| Feres, F | 1 |
| Abizaid, A | 1 |
| Gilard, M | 1 |
| Morice, MC | 1 |
| Kim, HS | 2 |
| Park, KW | 1 |
| Colombo, A | 1 |
| Chieffo, A | 1 |
| Sangiorgi, D | 1 |
| Biondi-Zoccai, G | 1 |
| Pufulete, M | 1 |
| White, J | 1 |
| Kayacioglu, I | 1 |
| Gunay, R | 1 |
| Saskin, H | 1 |
| Idiz, M | 1 |
| Sensoz, Y | 1 |
| Ates, M | 1 |
| Tangurek, B | 1 |
| Alper, AT | 1 |
| Demirtas, MM | 1 |
| Yekeler, I | 1 |
| Hasegawa, T | 1 |
| Elder, SJ | 1 |
| Bragg-Gresham, JL | 1 |
| Pisoni, RL | 1 |
| Yamazaki, S | 1 |
| Akizawa, T | 1 |
| Jadoul, M | 1 |
| Hugh, RC | 1 |
| Port, FK | 1 |
| Fukuhara, S | 1 |
| Gori, AM | 2 |
| Marcucci, R | 2 |
| Migliorini, A | 1 |
| Valenti, R | 1 |
| Moschi, G | 1 |
| Paniccia, R | 2 |
| Buonamici, P | 2 |
| Gensini, GF | 2 |
| Vergara, R | 1 |
| Abbate, R | 2 |
| Antoniucci, D | 2 |
| Trenk, D | 1 |
| Milani, RV | 1 |
| Giusti, B | 1 |
| Saracini, C | 1 |
| Sestini, I | 1 |
| Dean, J | 1 |
| Yujie, Z | 1 |
| Yingxin, Z | 1 |
| Yuyang, L | 1 |
| Yonghe, G | 1 |
| Wanjun, C | 1 |
| Zheng, C | 1 |
| Cuisset, T | 1 |
| Frere, C | 1 |
| Quilici, J | 1 |
| Gaborit, B | 1 |
| Bali, L | 1 |
| Poyet, R | 1 |
| Faille, D | 1 |
| Morange, PE | 1 |
| Alessi, MC | 1 |
| Bonnet, JL | 1 |
| Hu, PP | 1 |
| Peterson, KL | 1 |
| Tsimikas, S | 1 |
| Pecot, CV | 1 |
| Fuller, M | 1 |
| Muldowney, JA | 1 |
| Misra, S | 1 |
| Dixon, BS | 3 |
| Beck, GJ | 3 |
| Vazquez, MA | 1 |
| Greenberg, A | 1 |
| Delmez, JA | 1 |
| Allon, M | 1 |
| Dember, LM | 3 |
| Gassman, JJ | 3 |
| Greene, T | 3 |
| Radeva, MK | 1 |
| Davidson, IJ | 1 |
| Ikizler, TA | 1 |
| Braden, GL | 1 |
| Fenves, AZ | 1 |
| Kaufman, JS | 3 |
| Cotton, JR | 1 |
| Martin, KJ | 1 |
| McNeil, JW | 1 |
| Rahman, A | 1 |
| Lawson, JH | 3 |
| Whiting, JF | 3 |
| Hu, B | 1 |
| Meyers, CM | 2 |
| Kusek, JW | 2 |
| Feldman, HI | 3 |
| Lok, CE | 1 |
| Gao, C | 1 |
| Ren, C | 1 |
| Li, D | 1 |
| Li, L | 1 |
| Esposito, RA | 1 |
| Wang, ZJ | 1 |
| Zhou, YJ | 1 |
| Liu, YY | 1 |
| Yu, M | 1 |
| Shi, DM | 1 |
| Zhao, YX | 1 |
| Guo, YH | 1 |
| Cheng, WJ | 1 |
| Nie, B | 1 |
| Ge, HL | 1 |
| Jia, DA | 1 |
| Yang, SW | 1 |
| Yan, ZX | 1 |
| Sanioglu, S | 1 |
| Tetik, S | 1 |
| Sokullu, O | 1 |
| Deniz, H | 1 |
| Aydemir, N | 1 |
| Yilmaz, M | 1 |
| Arslan, IY | 1 |
| Bilgen, F | 1 |
| Pinto Slottow, TL | 1 |
| Bonello, L | 1 |
| Gavini, R | 1 |
| Beauzile, P | 1 |
| Sushinsky, SJ | 1 |
| Scheinowitz, M | 1 |
| Kaneshige, K | 1 |
| Xue, Z | 1 |
| Torguson, R | 1 |
| Tantry, U | 1 |
| Pichard, AD | 2 |
| Satler, LF | 2 |
| Suddath, WO | 1 |
| Kent, K | 1 |
| Gurbel, P | 2 |
| Waksman, R | 2 |
| Weale, AR | 1 |
| Cooper, DG | 1 |
| Hentschel, DM | 1 |
| Wilson, AM | 1 |
| Brittenden, J | 1 |
| Bachoo, P | 1 |
| Ford, I | 1 |
| Nixon, GF | 1 |
| Geisler, T | 1 |
| Zürn, C | 1 |
| Simonenko, R | 1 |
| Rapin, M | 1 |
| Kraibooj, H | 1 |
| Kilias, A | 1 |
| Bigalke, B | 1 |
| Stellos, K | 1 |
| Schwab, M | 1 |
| May, AE | 1 |
| Herdeg, C | 1 |
| Gawaz, M | 1 |
| Popescu, WM | 1 |
| Chun, KJ | 1 |
| Park, SW | 1 |
| Yun, SC | 1 |
| Kim, WJ | 2 |
| Lee, JY | 2 |
| Park, DW | 1 |
| Lee, CW | 1 |
| Rhee, KS | 1 |
| Chae, JK | 1 |
| Ko, JK | 1 |
| Park, JH | 1 |
| Lee, JH | 1 |
| Choi, SW | 1 |
| Jeong, JO | 1 |
| Seong, IW | 1 |
| Jon, S | 1 |
| Lee, NH | 1 |
| Kim, JH | 1 |
| Belch, JJ | 1 |
| Dormandy, J | 1 |
| Biasi, GM | 1 |
| Biasi, BM | 1 |
| Cairols, M | 1 |
| Diehm, C | 1 |
| Eikelboom, B | 1 |
| Golledge, J | 1 |
| Jawien, A | 1 |
| Lepäntalo, M | 1 |
| Norgren, L | 1 |
| Hiatt, WR | 1 |
| Becquemin, JP | 1 |
| Bergqvist, D | 3 |
| Clement, D | 1 |
| Baumgartner, I | 1 |
| Minar, E | 1 |
| Stonebridge, P | 1 |
| Vermassen, F | 1 |
| Matyas, L | 1 |
| Leizorovicz, A | 1 |
| Harmsze, AM | 2 |
| van Werkum, JW | 2 |
| Zwart, B | 1 |
| Bouman, HJ | 2 |
| Breet, NJ | 2 |
| van 't Hof, AW | 1 |
| Ruven, HJ | 1 |
| Klungel, OH | 1 |
| de Boer, A | 1 |
| Deneer, VH | 1 |
| Huber, K | 2 |
| Veeger, NJ | 1 |
| Zijlstra, F | 1 |
| Hillege, HL | 3 |
| van der Meer, J | 4 |
| Hiratzka, LF | 1 |
| Gao, G | 1 |
| Pi, Y | 1 |
| Lu, B | 1 |
| Hu, S | 1 |
| Sun, JC | 1 |
| Teoh, KH | 1 |
| Ellins, ML | 1 |
| Jung, H | 1 |
| Anand, S | 1 |
| Whitlock, RP | 1 |
| Eikelboom, JW | 1 |
| Kozuma, K | 1 |
| Ota, Y | 1 |
| Nagai, Y | 1 |
| Katsuta, Y | 1 |
| Nozaki, E | 1 |
| Onodera, T | 1 |
| Ikari, Y | 2 |
| Kotani, J | 1 |
| Kyo, E | 1 |
| Yokoi, H | 1 |
| Nakamura, M | 2 |
| Gluckman, TJ | 1 |
| McLean, RC | 1 |
| Schulman, SP | 1 |
| Kickler, TS | 1 |
| Shapiro, EP | 1 |
| Conte, JV | 1 |
| McNicholas, KW | 1 |
| Segal, JB | 1 |
| Rade, JJ | 1 |
| Sibbing, D | 1 |
| Koch, W | 1 |
| Massberg, S | 1 |
| Byrne, RA | 1 |
| Mehilli, J | 2 |
| Schulz, S | 1 |
| Mayer, K | 1 |
| Bernlochner, I | 1 |
| Schömig, A | 2 |
| Kastrati, A | 2 |
| Refiker, M | 1 |
| Conte, MS | 2 |
| Koul, S | 1 |
| Smith, JG | 1 |
| Scherstén, F | 1 |
| James, S | 1 |
| Lagerqvist, B | 1 |
| Erlinge, D | 1 |
| Gasparovic, H | 2 |
| Petricevic, M | 2 |
| Biocina, B | 2 |
| Bisdas, T | 1 |
| Haverich, A | 2 |
| Teebken, OE | 1 |
| Kuznetsov, MR | 1 |
| Rodionov, SV | 1 |
| Koshkin, VM | 1 |
| Virganskiĭ, AO | 1 |
| Golosnitskiĭ, PIu | 1 |
| Tepliakov, SA | 1 |
| Kosykh, IV | 1 |
| Ostapchuk, NA | 1 |
| Lisenkov, OP | 1 |
| Chernikov, VP | 1 |
| Konosic, S | 1 |
| Kopjar, T | 1 |
| Kunac, N | 1 |
| Avlonitis, VS | 1 |
| Planas, S | 1 |
| Hayes, AM | 1 |
| Parry, A | 1 |
| Sambu, N | 1 |
| Radhakrishnan, A | 1 |
| Dent, H | 1 |
| Calver, AL | 1 |
| Corbett, S | 1 |
| Gray, H | 1 |
| Simpson, IA | 1 |
| Curzen, N | 1 |
| Monaco, M | 1 |
| Di Tommaso, L | 1 |
| Pinna, GB | 1 |
| Lillo, S | 1 |
| Schiavone, V | 1 |
| Stassano, P | 1 |
| Kizilkilic, O | 1 |
| Kocer, N | 1 |
| Metaxas, GE | 1 |
| Babic, D | 1 |
| Homan, R | 1 |
| Islak, C | 1 |
| Jang, JS | 1 |
| Jin, HY | 1 |
| Seo, JS | 1 |
| Yang, TH | 1 |
| Kim, DK | 2 |
| Kim, DS | 1 |
| Seol, SH | 1 |
| Kim, DI | 1 |
| Cho, KI | 1 |
| Kim, BH | 1 |
| Park, YH | 1 |
| Je, HG | 1 |
| Jeong, YH | 1 |
| Pattanaik, D | 1 |
| Lieberman, P | 1 |
| Das, P | 1 |
| Ajani, AE | 1 |
| Pinnow, E | 1 |
| Cheneau, E | 1 |
| Leborgne, L | 1 |
| Dieble, R | 1 |
| Bui, AB | 1 |
| Kent, KK | 1 |
| Lindsay, J | 1 |
| Farb, A | 1 |
| John, M | 1 |
| Acampado, E | 1 |
| Kolodgie, FD | 1 |
| Prescott, MF | 1 |
| Virmani, R | 1 |
| Kim, MH | 1 |
| Cha, KS | 1 |
| Han, JY | 1 |
| Kim, HJ | 1 |
| Saran, R | 1 |
| Dykstra, DM | 1 |
| Wolfe, RA | 1 |
| Gillespie, B | 1 |
| Held, PJ | 1 |
| Young, EW | 1 |
| Mueller, C | 1 |
| Roskamm, H | 1 |
| Hunziker, P | 1 |
| Marsch, S | 1 |
| Perruchoud, A | 1 |
| Buettner, HJ | 1 |
| Strike, PC | 1 |
| Robinson, NM | 1 |
| Dymond, DS | 1 |
| Mahmood, A | 1 |
| Sintler, M | 1 |
| Edwards, AT | 1 |
| Smith, SR | 1 |
| Simms, MH | 1 |
| Vohra, RK | 1 |
| Ortolani, P | 1 |
| Marzocchi, A | 1 |
| Gaiba, W | 1 |
| Neri, S | 1 |
| Marrozzini, C | 1 |
| Aquilina, M | 1 |
| Branzi, A | 1 |
| Lim, E | 1 |
| Ali, Z | 1 |
| Ali, A | 1 |
| Routledge, T | 1 |
| Edmonds, L | 1 |
| Altman, DG | 1 |
| Large, S | 1 |
| Smout, JD | 1 |
| Mikhailidis, DP | 1 |
| Shenton, BK | 1 |
| Stansby, G | 1 |
| Johnson, W | 1 |
| Berger, PB | 1 |
| Jiménez-Quevedo, P | 1 |
| Bernardo, E | 1 |
| Sabaté, M | 2 |
| Torsney, E | 1 |
| Mayr, U | 1 |
| Zou, Y | 1 |
| Thompson, WD | 1 |
| Hu, Y | 1 |
| Xu, Q | 1 |
| Panneton, JM | 1 |
| Hollier, LH | 1 |
| Hofer, JM | 1 |
| Stiefelhagen, P | 1 |
| Tsuda, E | 1 |
| Kitamura, S | 1 |
| Stein, PD | 2 |
| Schünemann, HJ | 1 |
| Dalen, JE | 2 |
| Gutterman, D | 1 |
| Yilmaz, MB | 1 |
| Balbay, Y | 1 |
| Caldir, V | 1 |
| Ayaz, S | 1 |
| Guray, Y | 1 |
| Guray, U | 1 |
| Korkmaz, S | 1 |
| Ferrari, E | 1 |
| Benhamou, M | 1 |
| Cerboni, P | 1 |
| Marcel, B | 1 |
| Poston, R | 1 |
| Gu, J | 2 |
| Brown, J | 2 |
| Gammie, J | 2 |
| White, C | 2 |
| Manchio, J | 1 |
| Pierson, RN | 2 |
| Griffith, BP | 2 |
| Tandry, U | 2 |
| Gilbert, TB | 1 |
| Ariesen, MJ | 1 |
| Tangelder, MJ | 5 |
| Lawson, JA | 5 |
| Eikelboom, BC | 5 |
| Grobbee, DE | 1 |
| Algra, A | 5 |
| Mehta, SR | 1 |
| Aranki, SF | 1 |
| Ouriel, K | 1 |
| Wholey, MH | 1 |
| Fayad, P | 1 |
| Katzen, BT | 1 |
| Whitlow, P | 1 |
| Frentzko, M | 1 |
| Kuntz, RE | 2 |
| Wechsler, L | 1 |
| Hopkins, N | 1 |
| Satler, L | 1 |
| Mishkel, G | 1 |
| Yadav, JS | 2 |
| Bocek, P | 1 |
| Depner, TA | 1 |
| Hunsicker, LG | 2 |
| Middleton, JP | 2 |
| Radeva, M | 2 |
| Schwab, SJ | 2 |
| Poston, RS | 1 |
| Lee, A | 1 |
| Connerney, I | 1 |
| Avari, T | 1 |
| Christenson, R | 1 |
| Miwa, S | 1 |
| Desai, N | 1 |
| Koyama, T | 1 |
| Chan, E | 1 |
| Cohen, EA | 1 |
| Jai Shankar, K | 1 |
| Jaiswal, P | 1 |
| Cherian, KM | 1 |
| Faggioli, GL | 1 |
| Ferri, M | 1 |
| Rossi, C | 1 |
| Gargiulo, M | 1 |
| Freyrie, A | 1 |
| Stella, A | 1 |
| Hata, M | 1 |
| Sezai, A | 1 |
| Niino, T | 1 |
| Yoda, M | 1 |
| Wakui, S | 1 |
| Chiku, M | 1 |
| Honye, J | 1 |
| Saitoh, S | 1 |
| Minami, K | 1 |
| Luxembourg, B | 1 |
| Mani, H | 1 |
| Toennes, SW | 1 |
| Strubel, G | 1 |
| Klaeffling, C | 1 |
| Daemgen-von Brevern, G | 1 |
| Geisen, C | 1 |
| Lindhoff-Last, E | 1 |
| Danenberg, HD | 1 |
| Shauer, A | 1 |
| Gilon, D | 1 |
| Wan, S | 1 |
| Shukla, N | 1 |
| Yim, AP | 1 |
| Johnson, JL | 1 |
| Jeremy, JY | 1 |
| Prabhakaran, S | 1 |
| Wells, KR | 1 |
| Lee, VH | 1 |
| Flaherty, CA | 1 |
| Lopes, DK | 1 |
| Rossini, R | 1 |
| Musumeci, G | 1 |
| Scuri, P | 1 |
| Invernizzi, P | 1 |
| Bass, TA | 1 |
| Mihalcsik, L | 1 |
| Gavazzi, A | 1 |
| Zimmermann, N | 1 |
| Gams, E | 1 |
| Hohlfeld, T | 1 |
| Hillis, LD | 1 |
| Rivey, MP | 1 |
| Alexander, MR | 1 |
| Taylor, JW | 1 |
| Moor, E | 1 |
| Hamsten, A | 1 |
| Blombäck, M | 1 |
| Herzfeld, I | 1 |
| Wiman, B | 1 |
| Rydén, L | 1 |
| Lindblad, B | 2 |
| Wakefield, TW | 1 |
| Stanley, TJ | 1 |
| Nichol, BJ | 1 |
| Greenfield, LJ | 1 |
| Stanley, JC | 1 |
| Bergentz, SE | 1 |
| Mudra, H | 1 |
| Valji, K | 2 |
| Bookstein, JJ | 2 |
| Roberts, AC | 2 |
| Oglevie, SB | 1 |
| Pittman, C | 1 |
| O'Neill, MP | 1 |
| Basile, AP | 1 |
| Fiala, TG | 1 |
| Yaremchuk, MJ | 1 |
| May, JW | 1 |
| Mohan, CR | 1 |
| Sharp, WJ | 1 |
| Hoballah, JJ | 1 |
| Kresowik, TF | 1 |
| Schueppert, MT | 1 |
| Corson, JD | 1 |
| London, NJ | 1 |
| Varty, K | 1 |
| Thompson, M | 1 |
| Sayers, RD | 1 |
| Bell, PR | 1 |
| Galea, J | 1 |
| Manché, A | 1 |
| Goiti, JJ | 1 |
| Locke, TJ | 1 |
| Wilkinson, GA | 1 |
| Smith, GH | 1 |
| Brutel de la Rivière, A | 1 |
| van Gilst, WH | 2 |
| Pfisterer, M | 5 |
| Kootstra, GJ | 2 |
| Dunselman, PH | 1 |
| Mulder, BJ | 3 |
| Lie, KI | 2 |
| Edmondson, RA | 1 |
| Cohen, AT | 1 |
| Das, SK | 1 |
| Wagner, MB | 1 |
| Kakkar, VV | 1 |
| Kallis, P | 1 |
| Tooze, JA | 1 |
| Talbot, S | 1 |
| Cowans, D | 1 |
| Bevan, DH | 1 |
| Treasure, T | 1 |
| van der Doef, RM | 1 |
| van der Wall, EE | 1 |
| Tijssen, JG | 1 |
| Piek, JJ | 1 |
| Dunning, AJ | 1 |
| Gershlick, AH | 3 |
| Sreedhara, R | 1 |
| Lazarus, JM | 1 |
| Hakim, RM | 1 |
| Ascoop, CA | 1 |
| Loeliger, EA | 4 |
| Houben, JJ | 2 |
| Nicolai, G | 2 |
| Goldman, S | 5 |
| Copeland, J | 3 |
| Moritz, T | 4 |
| Henderson, W | 3 |
| Zadina, K | 4 |
| Ovitt, T | 3 |
| Kern, KB | 2 |
| Sethi, G | 2 |
| Sharma, GV | 2 |
| Khuri, S | 2 |
| Visser, J | 1 |
| Rajah, SM | 2 |
| Nair, U | 1 |
| Rees, M | 1 |
| Saunders, N | 1 |
| Walker, D | 1 |
| Williams, G | 1 |
| Critchley, A | 1 |
| Beton, D | 1 |
| Campbell, C | 1 |
| Lawson, RA | 1 |
| Bearn, PE | 2 |
| Bull, H | 2 |
| Seddon, AM | 2 |
| Marston, A | 2 |
| McCollum, CN | 4 |
| Cataldo, G | 3 |
| Braga, M | 1 |
| Pirotta, N | 1 |
| Lavezzari, M | 2 |
| Rovelli, F | 2 |
| Marubini, E | 3 |
| Verheugt, FW | 1 |
| van der Meer, FJ | 1 |
| Rosendaal, FR | 1 |
| Urquhart, J | 1 |
| Thijssen, H | 1 |
| Struijker Boudier, HA | 1 |
| Sanchez, RB | 1 |
| Hess, F | 2 |
| Steeghs, S | 2 |
| Jerusalem, R | 1 |
| Reijnders, O | 1 |
| Jerusalem, C | 2 |
| Braun, B | 2 |
| Grande, P | 2 |
| Hockings, BE | 1 |
| Ireland, MA | 1 |
| Gotch-Martin, KF | 1 |
| Taylor, RR | 1 |
| Rohn, V | 2 |
| Pirk, J | 3 |
| Mach, T | 1 |
| Saad, EM | 1 |
| Kaplan, S | 2 |
| el-Massry, S | 1 |
| Kaplan, A | 1 |
| Marcoe, KF | 2 |
| Zammit, M | 2 |
| Fisher, LD | 2 |
| Sauvage, LR | 2 |
| Sarin, S | 1 |
| Shami, SK | 1 |
| Cheatle, TR | 1 |
| Bearn, P | 1 |
| Scurr, JH | 1 |
| Coleridge Smith, PD | 1 |
| Moffat, C | 1 |
| Fox, B | 1 |
| Levinton, C | 1 |
| Naylor, CD | 1 |
| Chen, E | 1 |
| Christakis, GT | 1 |
| Goldman, BS | 1 |
| Hirko, MK | 2 |
| McShannic, JR | 1 |
| Schmidt, SP | 3 |
| Sharp, WV | 3 |
| Evancho, MM | 3 |
| Sims, RL | 1 |
| Siebert, JD | 1 |
| Harvey, R | 1 |
| Bredenberg, CE | 1 |
| Couper, L | 1 |
| Brothers, TE | 1 |
| Robison, JG | 1 |
| Elliott, BM | 1 |
| Boggs, JM | 1 |
| Halushka, PV | 1 |
| Wittwer, T | 1 |
| Wahlers, T | 1 |
| Dresler, C | 1 |
| Belkin, M | 1 |
| Donaldson, MC | 1 |
| Whittemore, AD | 1 |
| Heiman, F | 1 |
| Alderman, EL | 1 |
| Levy, JH | 1 |
| Rich, JB | 1 |
| Nili, M | 1 |
| Vidne, B | 1 |
| Schaff, H | 1 |
| Uretzky, G | 1 |
| Pettersson, G | 1 |
| Thiis, JJ | 1 |
| Hantler, CB | 1 |
| Chaitman, B | 1 |
| Nadel, A | 1 |
| Makkar, RR | 1 |
| Eigler, NL | 1 |
| Kaul, S | 1 |
| Frimerman, A | 1 |
| Shah, PK | 1 |
| Forrester, JS | 1 |
| Herbert, JM | 1 |
| Litvack, F | 1 |
| Théroux, P | 1 |
| Jackson, MR | 2 |
| Clagett, GP | 2 |
| Reifart, N | 1 |
| Störger, H | 1 |
| Schwarz, F | 1 |
| Rabe, A | 1 |
| Wardeh, AJ | 1 |
| Kay, IP | 1 |
| Coen, VL | 1 |
| Gijzel, AL | 1 |
| Ligthart, JM | 1 |
| den Boer, A | 1 |
| Levendag, PC | 1 |
| van Der Giessen, WJ | 1 |
| Serruys, PW | 1 |
| Karl, TR | 1 |
| Motz, R | 1 |
| Wessel, A | 1 |
| Ruschewski, W | 1 |
| Bürsch, J | 1 |
| Yoon, Y | 1 |
| Shim, WH | 1 |
| Lee, DH | 1 |
| Pyun, WB | 1 |
| Kim, IJ | 1 |
| Cho, SY | 1 |
| Van Langenhove, G | 1 |
| Vermeersch, P | 1 |
| Serrano, P | 1 |
| Kutryk, MJ | 1 |
| Stockman, D | 1 |
| Convens, C | 1 |
| Van den Branden, F | 1 |
| Vanagt, E | 1 |
| Albertal, M | 1 |
| Van den Heuvel, P | 1 |
| Gottsauner-Wolf, M | 1 |
| Zasmeta, G | 1 |
| Hornykewycz, S | 1 |
| Nikfardjam, M | 1 |
| Stepan, E | 1 |
| Wexberg, P | 1 |
| Zorn, G | 1 |
| Glogar, D | 1 |
| Probst, P | 1 |
| Maurer, G | 1 |
| Dirschinger, J | 1 |
| Dotzer, F | 1 |
| von Welser, N | 1 |
| Kiesz, RS | 1 |
| Buszman, P | 1 |
| Martin, JL | 1 |
| Deutsch, E | 1 |
| Rozek, MM | 1 |
| Gaszewska, E | 1 |
| Rewicki, M | 1 |
| Seweryniak, P | 1 |
| Kosmider, M | 1 |
| Tendera, M | 1 |
| Hennekes, S | 1 |
| Cutlip, DE | 1 |
| Baim, DS | 1 |
| Ho, KK | 1 |
| Popma, JJ | 1 |
| Lansky, AJ | 1 |
| Cohen, DJ | 1 |
| Carrozza, JP | 1 |
| Chauhan, MS | 1 |
| Rodriguez, O | 1 |
| Kuroda, Y | 1 |
| Hara, K | 1 |
| Nakajima, H | 1 |
| Anand, SS | 1 |
| Walenga, JM | 1 |
| Hoppensteadt, D | 1 |
| Pifarré, R | 1 |
| Fox, NL | 1 |
| Forman, S | 1 |
| Hunninghake, DB | 1 |
| Campeau, L | 2 |
| Herd, JA | 1 |
| Hoogwerf, BJ | 1 |
| Hickey, A | 1 |
| Probstfield, JL | 1 |
| Terrin, ML | 1 |
| Mukherjee, D | 1 |
| Chew, DP | 1 |
| Robbins, M | 1 |
| Raymond, RE | 1 |
| Moliterno, DJ | 1 |
| Zurbrügg, HR | 1 |
| Musci, M | 1 |
| Sänger, S | 1 |
| Gutersohn, A | 1 |
| Mülling, C | 1 |
| Wellnhofer, E | 1 |
| Schaffner, T | 1 |
| Hetzer, R | 1 |
| van der Zaag, ES | 1 |
| Legemate, DA | 1 |
| Duran, E | 1 |
| Canbaz, S | 1 |
| Ege, T | 1 |
| Acipayam, M | 1 |
| Johnson, WC | 1 |
| Williford, WO | 1 |
| Valentine, RJ | 1 |
| Piamsomboon, C | 1 |
| Laothavorn, P | 1 |
| Chatlaong, B | 1 |
| Saguanwong, S | 1 |
| Nasawadi, C | 1 |
| Tanprasert, P | 1 |
| Leelaprute, M | 1 |
| Intayakorn, U | 1 |
| Amornsak, N | 1 |
| Cosgrove, DM | 1 |
| Heric, B | 1 |
| Lytle, BW | 1 |
| Taylor, PC | 1 |
| Novoa, R | 1 |
| Golding, LA | 1 |
| Stewart, RW | 1 |
| McCarthy, PM | 1 |
| Loop, FD | 1 |
| Darius, H | 1 |
| Meyer, J | 1 |
| Schröder, H | 1 |
| Schrör, K | 1 |
| Landymore, RW | 3 |
| MacAulay, MA | 2 |
| Fris, J | 2 |
| Yli-Mäyry, S | 1 |
| Huikuri, HV | 1 |
| Korhonen, UR | 1 |
| Airaksinen, KE | 1 |
| Ikäheimo, MJ | 1 |
| Linnaluoto, MK | 1 |
| Takkunen, JT | 1 |
| Chong, BH | 1 |
| Agnew, TM | 1 |
| French, JK | 1 |
| Neutze, JM | 1 |
| Whitlock, RM | 1 |
| Brandt, PW | 1 |
| Kerr, AR | 1 |
| Webber, BJ | 1 |
| Rutherford, JD | 1 |
| Rezkalla, S | 1 |
| Reinhart, R | 1 |
| Waters, D | 1 |
| Gruss, JD | 1 |
| Hiemer, W | 1 |
| Kroiss, A | 1 |
| Geissler, C | 1 |
| Sagnol, P | 1 |
| Delahaye, JP | 1 |
| Mantz, F | 1 |
| Freund, M | 1 |
| Cazenave, JP | 1 |
| Petch, MC | 1 |
| McCollum, C | 2 |
| Kenchington, G | 2 |
| Alexander, C | 2 |
| Franks, PJ | 2 |
| Greenhalgh, RM | 1 |
| Jones, DN | 1 |
| Rutherford, RB | 1 |
| Ikezawa, T | 1 |
| Nishikimi, N | 1 |
| Ishibashi, H | 1 |
| Whitehill, TA | 1 |
| Montoro, C | 1 |
| Mezzanotte, G | 1 |
| Petroccione, A | 1 |
| Greenhalgh, R | 1 |
| Gavaghan, TP | 2 |
| Gebski, V | 2 |
| Baron, DW | 2 |
| Ollivier, JP | 1 |
| Burkart, F | 3 |
| Jockers, G | 3 |
| Meyer, B | 2 |
| Regenass, S | 2 |
| Burckhardt, D | 2 |
| Schmitt, HE | 3 |
| Müller-Brand, J | 2 |
| Skarvan, K | 2 |
| Stulz, P | 3 |
| Sanz, G | 2 |
| Chesebro, JH | 9 |
| Hickie, JB | 1 |
| Krilis, SA | 1 |
| Low, J | 1 |
| Chesterman, CN | 1 |
| Bech, FR | 1 |
| Cronenwett, JL | 1 |
| McDaniel, MD | 1 |
| Ogletree, ML | 1 |
| Freeman, DH | 1 |
| Pajarón, A | 1 |
| Alegría, E | 1 |
| Coello, I | 1 |
| Cardona, M | 1 |
| Fournier, JA | 1 |
| Gómez-Recio, M | 1 |
| Ruano, J | 1 |
| Hidalgo, R | 1 |
| Medina, A | 1 |
| Peregrin, J | 1 |
| Weber, MA | 1 |
| Hasford, J | 1 |
| Taillens, C | 1 |
| Zitzmann, A | 1 |
| Hahalis, G | 1 |
| Seggewiss, H | 1 |
| Langbehn, AF | 1 |
| Fassbender, D | 1 |
| Buchwalsky, R | 1 |
| Theisen, K | 1 |
| Pepine, CJ | 1 |
| Buring, JE | 1 |
| Hennekens, CH | 1 |
| Sethi, GK | 1 |
| Copeland, JG | 1 |
| Henderson, WG | 1 |
| Shoenfeld, NA | 1 |
| Yeager, A | 1 |
| Connolly, R | 1 |
| Ramberg, K | 2 |
| Forgione, L | 1 |
| Giorgio, A | 1 |
| Valeri, CR | 2 |
| Callow, AD | 2 |
| Stein, B | 1 |
| Fuster, V | 8 |
| Israel, DH | 1 |
| Cohen, M | 2 |
| Badimon, L | 1 |
| Badimon, JJ | 1 |
| Doherty, J | 1 |
| Read, R | 1 |
| Chesler, E | 1 |
| Sako, Y | 1 |
| Sarris, GE | 1 |
| Fann, JI | 1 |
| Sokoloff, MH | 1 |
| Smith, DL | 1 |
| Loveday, M | 1 |
| Kosek, JC | 2 |
| Stephens, RJ | 1 |
| Cooper, AD | 1 |
| May, K | 1 |
| Willis, AL | 1 |
| Matsumoto, M | 1 |
| Hunter, TJ | 2 |
| Falkow, LJ | 1 |
| Stratton, JR | 1 |
| Ritchie, JL | 1 |
| Eldrup-Jorgensen, J | 1 |
| Connolly, RJ | 1 |
| Mackey, WC | 1 |
| O'Donnell, TF | 1 |
| Sievert, H | 1 |
| Köhler, KP | 1 |
| Kaltenbach, M | 1 |
| Kober, G | 1 |
| Lyons, JP | 1 |
| Wright, JE | 1 |
| Sturridge, MF | 1 |
| Layton, CA | 1 |
| Balcon, R | 2 |
| Noppeney, T | 1 |
| Kasprzak, P | 1 |
| Raithel, D | 1 |
| Hirche, H | 1 |
| Curl, GR | 1 |
| Jakubowski, JA | 1 |
| Deykin, D | 1 |
| Bush, HL | 1 |
| Marrangoni, AG | 1 |
| Marcelli, G | 1 |
| Culig, M | 1 |
| Simone, ST | 1 |
| Freeman, MB | 1 |
| Sicard, GA | 1 |
| Valentin, LI | 1 |
| Neuberger, S | 1 |
| Mangino, MJ | 1 |
| Anderson, CB | 1 |
| Greenspan, B | 1 |
| Pillari, G | 1 |
| Schulman, ML | 1 |
| Badhey, M | 1 |
| Goldman, M | 1 |
| Steele, PM | 1 |
| van Det, R | 1 |
| Skotnicki, S | 1 |
| DeCampli, WM | 1 |
| Mitchell, RS | 1 |
| Handen, CE | 1 |
| Miller, DC | 1 |
| Harris, PL | 1 |
| Subramanian, VA | 1 |
| Hernandez, Y | 1 |
| Tack-Goldman, K | 1 |
| Grabowski, EF | 1 |
| Weksler, BB | 1 |
| Meier, B | 1 |
| Hasse, J | 1 |
| Grädel, E | 1 |
| Limet, R | 1 |
| Thaulow, E | 1 |
| Frøysaker, T | 1 |
| Dale, J | 1 |
| Vatne, K | 1 |
| Harker, LA | 2 |
| Wu, HD | 1 |
| Mathisen, SR | 1 |
| Walker, MW | 1 |
| Clowes, AW | 1 |
| Verstraete, M | 1 |
| Brown, BG | 2 |
| Ekeström, S | 1 |
| Henderson, AH | 1 |
| Jewitt, DE | 1 |
| Oliver, MF | 1 |
| Sleight, P | 1 |
| Patrono, C | 1 |
| Vojácek, J | 1 |
| Kovác, J | 1 |
| Donovan, DL | 1 |
| David, JL | 1 |
| Rosenthal, D | 1 |
| Mittenthal, MJ | 1 |
| Ruben, DM | 1 |
| Jones, DH | 1 |
| Estes, JW | 1 |
| Stanton, PE | 1 |
| Lamis, PA | 1 |
| Lane, IF | 1 |
| Irwin, JT | 1 |
| Jennings, SA | 1 |
| Poskitt, KR | 1 |
| Meek, AC | 1 |
| Hansen, KJ | 1 |
| Howe, HR | 1 |
| Edgerton, TA | 1 |
| Faust, KB | 1 |
| Kon, ND | 1 |
| Geisinger, KR | 1 |
| Meredith, JH | 1 |
| Nordestgaard, AG | 1 |
| Buckels, JA | 1 |
| Wilson, SE | 1 |
| Cukingnan, RA | 1 |
| DeRouen, T | 1 |
| Goede, LV | 1 |
| Wong, M | 1 |
| Fee, HJ | 1 |
| Roth, JA | 1 |
| Carey, JS | 1 |
| Brooks, N | 1 |
| Wright, J | 1 |
| Sturridge, M | 1 |
| Pepper, J | 1 |
| Magee, P | 1 |
| Walesby, R | 1 |
| Layton, C | 1 |
| Honey, M | 1 |
| Salter, MC | 1 |
| Donaldson, DR | 1 |
| Subba Rao, R | 1 |
| Boyle, RM | 1 |
| Partridge, JB | 1 |
| Watson, DA | 1 |
| Satiani, B | 1 |
| Bourassa, MG | 1 |
| Gillespie, MJ | 1 |
| McConney, M | 1 |
| Lespérance, J | 1 |
| Chesebro, JJ | 1 |
| Syndercombe Court, YD | 1 |
| Murday, AJ | 1 |
| Lewis, CT | 1 |
| Mills, PG | 1 |
| MacAulay, M | 1 |
| Sheridan, B | 1 |
| Cameron, C | 1 |
| Boerboom, LE | 1 |
| Olinger, GN | 1 |
| Bonchek, LI | 1 |
| Gunay, II | 1 |
| Kissebah, AH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| One Month Dual Antiplatelet Therapy With Ticagrelor in Coronary Artery Bypass Graft Patients[NCT05997693] | Phase 3 | 700 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery (The POPular CABG Study)[NCT02352402] | Phase 3 | 487 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Effects of High-dose Statin Treatments on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Drug-eluting Stents Implantation: a Randomized Controlled Study[NCT01557075] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2010-07-31 | Recruiting | ||
| Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET Trial): Does Ticagrelor Improve Graft Patency After Coronary Bypass?[NCT02053909] | Phase 4 | 250 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population[NCT00752128] | 2,349 participants (Actual) | Observational | 2008-08-31 | Completed | |||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm[NCT00726453] | 1,516 participants (Actual) | Interventional | 2008-07-31 | Completed | |||
| The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries[NCT00927940] | 100 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention[NCT00617084] | Phase 4 | 2,292 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial[NCT00476957] | Phase 4 | 8,709 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry[NCT01515345] | Phase 3 | 1,008 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Ticagrelor and Aspirin for the Prevention of Cardiovascular Events After Coronary Artery Bypass Surgery (CABG)[NCT01373411] | Phase 4 | 70 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Percutaneous Coronary Intervention: The PL-PLATELET Randomized Trial[NCT03078465] | Phase 3 | 0 participants (Actual) | Interventional | 2017-06-20 | Withdrawn (stopped due to Competitive studies were conducted at the same time, and enrollment was suspended.) | ||
| Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation[NCT00774475] | Phase 3 | 442 participants (Anticipated) | Interventional | 2008-11-30 | Not yet recruiting | ||
| Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency[NCT00067119] | Phase 3 | 649 participants (Actual) | Interventional | 2003-01-01 | Completed | ||
| Effect of Beraprost Sodium (Berasil) on Hemodialysis[NCT03142360] | 60 participants (Anticipated) | Interventional | 2017-04-05 | Recruiting | |||
| Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.[NCT00174759] | Phase 3 | 1,460 participants (Anticipated) | Interventional | 2004-09-30 | Completed | ||
| Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).[NCT01761786] | Phase 4 | 2,700 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [NCT00776477] | Phase 3 | 300 participants (Anticipated) | Interventional | 2007-12-31 | Recruiting | ||
| Pilot Study of Preoperative Aspirin and Postoperative Clopidogrel's Effects on Graft Patency and Cardiac Events in Coronary Artery Bypass Surgery[NCT00330772] | Phase 3 | 150 participants (Anticipated) | Interventional | 2006-07-31 | Completed | ||
| Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)[NCT00352014] | 1,000 participants (Anticipated) | Observational | 2006-01-31 | Completed | |||
| Relationship Between Level of Glycosylated Hemoglobin and Platelet Function in Patients Undergoing Coronary Artery Bypass Grafting[NCT02711124] | 130 participants (Anticipated) | Observational [Patient Registry] | 2014-02-28 | Recruiting | |||
| Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age[NCT00833703] | Phase 3 | 49 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Ovine Graft (Omniflow II) Versus PTFE in Below Knee Arterial Reconstruction: A Prospective Randomized Multi Centre Study[NCT00845585] | 0 participants (Actual) | Interventional | 2009-01-31 | Withdrawn (stopped due to found not enough centers for recruitment) | |||
| Maintenance of an Antiaggregation by Acetylsalicylic Acid, Less or Equal to 250mg While a Extracorporeal Lithotripsy (ECL) Session on a Kidney Stone is Perfomed: Comparative Unicentric Prospective Study[NCT03437057] | 300 participants (Anticipated) | Interventional | 2018-01-08 | Recruiting | |||
| A Double-blind, Randomized, Placebo Controlled Pilot Trial to Evaluate the Safety and Efficacy of Vorapaxar in Maturation of Arteriovenous Fistulae for Hemodialysis Access[NCT02475837] | Phase 2 | 17 participants (Actual) | Interventional | 2015-08-26 | Completed | ||
| Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis[NCT03289520] | Phase 3 | 877 participants (Actual) | Interventional | 2003-01-07 | Completed | ||
| A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome[NCT03007524] | Phase 4 | 80 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | ||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice[NCT01397175] | 1,960 participants (Actual) | Interventional | 2013-01-16 | Terminated (stopped due to Slow enrollment) | |||
| Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667] | 43 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| Intraoperative Optical Coherence Tomography of the Saphenous Vein Conduit in Patients Undergoing Coronary Artery Bypass Surgery[NCT05129228] | 760 participants (Anticipated) | Interventional | 2022-04-04 | Recruiting | |||
| [NCT00000489] | Phase 3 | 0 participants | Interventional | 1973-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary objective of this clinical trial will be to evaluate whether, as compared to usual aspirin treatment, ticagrelor early after CABG prevents saphenous vein graft occlusion 1 year after surgery, as assessed by computed tomography (CT) coronary angiography. (NCT02053909)
Timeframe: 1 year after surgery
| Intervention | percentage of veins occluded (Number) |
|---|---|
| Aspirin | 17.4 |
| Ticagrelor | 13.2 |
The secondary objective of this clinical trial will be to evaluate whether, as compared to usual aspirin treatment, ticagrelor early after CABG prevents saphenous vein graft stenosis, defined as >50% narrowing of the graft, 1 year after surgery, as assessed by computed tomography (CT) coronary angiography. (NCT02053909)
Timeframe: 1 year after surgery
| Intervention | percentage of veins stenosed (Number) |
|---|---|
| Aspirin | 4.1 |
| Ticagrelor | 4.2 |
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
(NCT00752128)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Cardiac Death or Target Vessel MI | 4.2 |
(NCT00752128)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Overall Stent Thrombosis (Definite and Probable-ARC) | 0.9 |
(NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 1.3 |
Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 5.5 |
Stent Thrombosis (ST) (as determined by historic and ARC definitions). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 0.1 |
Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods. (NCT00726453)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 4.7 |
Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 6.3 |
Target Vessel MI (as determined by extended historical and ARC definitions). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of eligible participants (Number) |
|---|---|
| Primary Enrollment Group | 1.4 |
The difference between the post-procedure immediate minimal lumen diameter (MLD) and follow up angigraphy MLD (NCT00927940)
Timeframe: Post procedure, 8 Months
| Intervention | mm (Mean) |
|---|---|
| Zotarolimus Eluting Stent | 0.13 |
Major Secondary Endpoint Target lesion fature (TLF) is defined as cardiac death, target vessel myocardial infarction(Q wave and non-Q wave), or clinically-driven target lesion revascularization (TLR) by percutaneous or surgical methods. (NCT00927940)
Timeframe: 12 months
| Intervention | percentage of participants with TLF (Number) |
|---|---|
| Zotarolims Eluting Stent | 4.0 |
In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory. (NCT00617084)
Timeframe: 13 Months
| Intervention | Percentage diameter stenosis (Mean) |
|---|---|
| 1. Resolute - 12-13 Months | 21.65 |
| 2. XIENCE V - 12-13 Months | 19.76 |
Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average. (NCT00617084)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| 1. Resolute - 12-13 Months | 8.2 |
| 2. XIENCE V - 12-13 Months | 8.3 |
Definite or probable stent thrombosis rate. (NCT00476957)
Timeframe: 3 years
| Intervention | participants (Number) |
|---|---|
| E-ZES | 61 |
| C-SES | 75 |
Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions (NCT00476957)
Timeframe: 3 years
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Total death and large non-fatal myocardial infarct | Total death and non-fatal myocardial infarctions | Cardiac death and large non-fatal MI | Cardiac death and non-fatal MI | Target lesion revascularization | Stroke | Bleeding events | |
| C-SES | 255 | 360 | 174 | 282 | 156 | 72 | 184 |
| E-ZES | 225 | 331 | 157 | 265 | 249 | 77 | 201 |
"Bleeding classified by the TIMI hemorrhage classification scheme:~Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to < 5 g/dL~Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of > 5 g/dL" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 17 |
| Individualized Therapy | 9 |
"The angiographic or pathological confirmation of stent thrombosis is called definite stent thrombosis" (NCT01515345)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 1 |
| Individualized Therapy | 0 |
"Probable stent thrombosis is considered to have occurred in case of~any unexplained death within the first 30 days.~any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 2 |
| Individualized Therapy | 0 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |
|---|---|---|
| Spontaneous | Puncture (vascular access site) | |
| Clopidogrel 0.2 mg/kg/Day | 1 | 1 |
| Placebo | 0 | 0 |
"All bleeding events experienced during the study period were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted." (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any bleeding event | - Serious | - Serious with an outcome of death | - Leading to permanent treatment discontinuation | |
| Clopidogrel 0.2 mg/kg/Day | 2 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 0 | 0 |
"Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded.~Participants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first)." (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |
|---|---|---|
| shunt thrombosis requiring intervention | death | |
| Clopidogrel 0.2 mg/kg/Day | 0 | 0 |
| Placebo | 0 | 1 |
Bleeding events according to GUSTO (criteria for bleeding: Severe, Moderate or Mild) and BARC (bleeding criteria Type 0-5, with 0 being no bleeding and 5 referring to probable or definite fatal bleeding) Criteria (NCT02475837)
Timeframe: up to 238 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Vorapaxar Intervention | 0 |
| Placebo Intervention | 1 |
Participants able to use their AV fistula for dialysis within 180 days of surgery were considered to have met the outcome. (NCT02475837)
Timeframe: up to 238 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Vorapaxar Intervention | 2 |
| Placebo Intervention | 4 |
Criteria for outcome: AV fistula patency at 150-180 days, with at least 50% increase in vein diameter by ultrasound compared with preoperative vein diameter measurement. (NCT02475837)
Timeframe: 150-238 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Vorapaxar Intervention | 1 |
| Placebo Intervention | 5 |
Time to AV fistula functional maturation (defined as successful cannulation of the AV fistula for six hemodialysis sessions within three weeks). (NCT02475837)
Timeframe: up to 238 days
| Intervention | Days to functional maturation (Median) |
|---|---|
| Vorapaxar Intervention | 169 |
| Placebo Intervention | 145 |
40 reviews available for aspirin and Graft Occlusion, Vascular
| Article | Year |
|---|---|
Ticagrelor for patients undergoing coronary artery bypass grafting: A meta-analysis of randomized controlled trials.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Hemorrhage; Humans; Platelet Aggregation | 2023 |
Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-analysis.
Topics: Aged; Aspirin; Coronary Artery Bypass; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; | 2022 |
Pathophysiology and Mechanisms of Saphenous Vein Graft Failure.
Topics: Aspirin; Graft Occlusion, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpla | 2022 |
A Meta-Analysis Comparing Aspirin Alone Versus Dual Antiplatelet Therapy for the Prevention of Venous Graft Failure Following Coronary Artery Bypass Surgery.
Topics: Aged; Aspirin; Bayes Theorem; Coronary Artery Bypass; Coronary Artery Disease; Dual Anti-Platelet Th | 2020 |
Meta-Analysis Comparing P2Y
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage | 2020 |
Dual Antiplatelet Therapy De-escalation Strategies.
Topics: Acute Coronary Syndrome; Aspirin; Drug Administration Schedule; Dual Anti-Platelet Therapy; Graft Oc | 2021 |
Role and Timing of Aspirin Therapy Following PCI in Patients With Atrial Fibrillation.
Topics: Aspirin; Atrial Fibrillation; Drug Administration Schedule; Dual Anti-Platelet Therapy; Graft Occlus | 2021 |
Meta-analysis of efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass grafting.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Thrombosis; Dual Anti-Platelet Therapy; Female; Graf | 2019 |
Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis.
Topics: Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Graft Occl | 2013 |
Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting.
Topics: Aspirin; Coronary Angiography; Coronary Artery Bypass; Graft Occlusion, Vascular; Humans; Platelet A | 2013 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Who might benefit from early aspirin after coronary artery surgery?
Topics: Aged; Aspirin; Benchmarking; Coronary Artery Bypass; Coronary Artery Disease; Coronary Thrombosis; D | 2014 |
Resistance to antiplatelet drugs: what progress has been made?
Topics: Aspirin; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Percutaneous Coronary Intervent | 2014 |
Use of antiplatelet drugs after cardiac operations.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combinatio | 2014 |
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.
Topics: Anastomosis, Surgical; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Graft Occlusion, Vas | 2015 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2017 |
Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Cardiovascular Diseas | 2009 |
A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Com | 2012 |
Indirect comparison meta-analysis of aspirin therapy after coronary surgery.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Coronary Disease; Graft Occlusion, Vascular; Humans; | 2003 |
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Aspirin; Clopidogrel; Contraindications; Coronary Artery Bypass; Coronary Disease; Dose-Response Rel | 2004 |
Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery.
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Coron | 2005 |
Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent.
Topics: Aspirin; Coronary Artery Bypass; Drug Administration Schedule; Drug Resistance; Fibrinolytic Agents; | 2008 |
Percutaneous transluminal coronary angioplasty.
Topics: Angina, Unstable; Angioplasty, Balloon; Animals; Aspirin; Calcium Channel Blockers; Coronary Artery | 1984 |
Dipyridamole: a critical evaluation.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1984 |
When do vascular surgeons prescribe antiplatelet therapy? Current attitudes.
Topics: Angioplasty, Balloon; Arteriosclerosis; Aspirin; Dipyridamole; Graft Occlusion, Vascular; Humans; Is | 1993 |
Optimal antithrombotic therapy following aortocoronary bypass: a meta-analysis.
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Drug Therapy, Combination; Graft Occl | 1993 |
Antithrombotic therapy in peripheral arterial occlusive disease.
Topics: Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Endarterectomy, C | 1998 |
Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery.
Topics: Administration, Oral; Amputation, Surgical; Anticoagulants; Aspirin; Graft Occlusion, Vascular; Huma | 1999 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
[Acetylsalicylic acid in unstable angina, after coronary revascularization and in prevention of cardiac thromboembolism].
Topics: Angina, Unstable; Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Heart Valve Prosthesis | 1992 |
[Clinical pharmacology of acetylsalicylic acid].
Topics: Administration, Oral; Animals; Aspirin; Biological Availability; Coronary Artery Bypass; Dose-Respon | 1992 |
[Anticoagulant or antiplatelet aggregation treatment after aortocoronary bypass].
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Occlusion, Vascular; Humans; Me | 1991 |
Platelet inhibitor agents in cardiovascular disease: an update.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Graf | 1989 |
Platelet-inhibitor drugs before and after coronary artery bypass surgery and coronary angioplasty: the basis of their use, data from animal studies, clinical trial data, and current recommendations.
Topics: Angioplasty, Balloon; Animals; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Coronar | 1986 |
Coronary artery bypass grafting. A model for the understanding of the progression of atherosclerotic disease and the role of pharmacological intervention.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Collagen; Coronary Artery Bypass | 1985 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
Role of platelets and platelet inhibitors in aortocoronary artery vein-graft disease.
Topics: Animals; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamole; D | 1986 |
Aspirin for the prevention of coronary thrombosis: current facts and perspectives.
Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disea | 1986 |
Long-term fate of bypass grafts: the Coronary Artery Surgery Study (CASS) and Montreal Heart Institute experiences.
Topics: Animals; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamole; Follow-Up Studies; | 1985 |
Aortocoronary artery vein-graft disease: experimental and clinical approach for the understanding of the role of platelets and platelet inhibitors.
Topics: Animals; Aspirin; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Dogs; Gra | 1985 |
110 trials available for aspirin and Graft Occlusion, Vascular
| Article | Year |
|---|---|
Ticagrelor versus aspirin and vein graft patency after coronary bypass: A randomized trial.
Topics: Aspirin; Coronary Angiography; Coronary Artery Bypass; Graft Occlusion, Vascular; Humans; Platelet A | 2022 |
Commentary: Prevention of saphenous vein graft disease remains elusive.
Topics: Aspirin; Graft Occlusion, Vascular; Humans; Platelet Aggregation Inhibitors; Saphenous Vein; Treatme | 2022 |
Ticagrelor versus aspirin 2 years after coronary bypass: Observational analysis from the TARGET trial.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Humans; Platelet Aggregation Inhibitors; | 2022 |
A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery-Rationale and design of the POPular CABG trial.
Topics: Aged; Aspirin; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; Death, | 2020 |
Influence of lipoproteins and antiplatelet agents on vein graft patency 1 year after coronary artery bypass grafting.
Topics: Aged; Aspirin; Biomarkers; China; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; | 2022 |
Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG): A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Double-Blind M | 2020 |
High-intensity Statin Treatments in Clinically Stable Patients on Aspirin Monotherapy 12 Months After Drug-eluting Stent Implantation: A Randomized Study.
Topics: Aspirin; Atorvastatin; Coronary Artery Disease; Drug-Eluting Stents; Female; Graft Occlusion, Vascul | 2018 |
Impact of ticagrelor versus aspirin on graft patency after CABG: Rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909).
Topics: Aftercare; Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Cor | 2018 |
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study.
Topics: Aged; Aspirin; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inh | 2019 |
Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft.
Topics: Adult; Arteriovenous Shunt, Surgical; Aspirin; Aspirin, Dipyridamole Drug Combination; Cost-Benefit | 2014 |
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
Topics: Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin | 2014 |
Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Aspirin; Australia; Comorbidity; Docosahexaenoic Acids; | 2016 |
Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery.
Topics: Adenosine; Aged; Aspirin; British Columbia; Chi-Square Distribution; Computed Tomography Angiography | 2016 |
Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Vessels; Drug Therapy, Combination; Elect | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D | 2016 |
Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis: A Randomized Clinical Trial.
Topics: Administration, Oral; Adult; Arteriovenous Shunt, Surgical; Aspirin; Constriction, Pathologic; Dieta | 2017 |
The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Graft Occlusion, Vascular; Humans; Male; Middl | 2008 |
Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Resista | 2008 |
Effect of dipyridamole plus aspirin on hemodialysis graft patency.
Topics: Aspirin; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; | 2009 |
Effect of dipyridamole plus aspirin on hemodialysis graft patency.
Topics: Aspirin; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; | 2009 |
Effect of dipyridamole plus aspirin on hemodialysis graft patency.
Topics: Aspirin; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; | 2009 |
Effect of dipyridamole plus aspirin on hemodialysis graft patency.
Topics: Aspirin; Delayed-Action Preparations; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; | 2009 |
Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Dose-Re | 2009 |
Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Biomarkers; Blotting, Western; Cell P | 2009 |
Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Diabete | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Fourteen-year follow-up from CABADAS: vitamin K antagonists or dipyridamole not superior to aspirin.
Topics: Acenocoumarol; Aged; Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Female; Follow-U | 2010 |
Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial.
Topics: Administration, Oral; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary A | 2010 |
Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Femal | 2010 |
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combinati | 2011 |
Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients.
Topics: Administration, Oral; Aged; Aspirin; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; | 2012 |
Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS.
Topics: Aspirin; Brachytherapy; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Female; Gamm | 2002 |
Effect of antioxidant probucol for preventing stent restenosis.
Topics: Aged; Antioxidants; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiography; Coronary Ar | 2002 |
A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Drug Ther | 2003 |
Combination antiplatelet therapy in patients with peripheral vascular bypass grafts.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Drug T | 2004 |
Multicenter randomized prospective trial comparing a pre-cuffed polytetrafluoroethylene graft to a vein cuffed polytetrafluoroethylene graft for infragenicular arterial bypass.
Topics: Aged; Aged, 80 and over; Anastomosis, Surgical; Anticoagulants; Arterial Occlusive Diseases; Aspirin | 2004 |
Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) Study.
Topics: Administration, Oral; Aged; Anticoagulants; Arteriosclerosis; Aspirin; Female; Fibrinolytic Agents; | 2005 |
Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting.
Topics: Aprotinin; Aspirin; Biomarkers; Blood Coagulation Tests; Blood Loss, Surgical; Coronary Artery Bypas | 2006 |
Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis; Cerebrovascular Disorders; Clopidogrel; C | 2008 |
Dipyridamole: a critical evaluation.
Topics: Angina Pectoris; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1984 |
Haemostatic factors and inhibitors and coronary artery bypass grafting: preoperative alterations and relations to graft occlusion.
Topics: Acute-Phase Proteins; Aged; Aspirin; Blood Coagulation; Blood Coagulation Factors; Coronary Artery B | 1994 |
[Prevention of occlusion following peripheral bypass surgery using oral anticoagulants or acetylsalicylic acid: a randomized comparison within the Dutch BOA study].
Topics: Anticoagulants; Aspirin; Blood Vessel Prosthesis; Femoral Artery; Graft Occlusion, Vascular; Humans; | 1995 |
A comparative evaluation of externally supported polytetrafluoroethylene axillobifemoral and axillounifemoral bypass grafts.
Topics: Aged; Aged, 80 and over; Anastomosis, Surgical; Aorta; Arteriosclerosis; Aspirin; Axillary Artery; B | 1995 |
Effects of low dose aspirin (50 mg/day), low dose aspirin plus dipyridamole, and oral anticoagulant agents after internal mammary artery bypass grafting: patency and clinical outcome at 1 year. CABADAS Research Group of the Interuniversity Cardiology Inst
Topics: Acenocoumarol; Anticoagulants; Aspirin; Dipyridamole; Double-Blind Method; Drug Therapy, Combination | 1994 |
Low-molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting.
Topics: Adult; Aged; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Femoral Artery; Graft Occlusi | 1994 |
Pre-operative aspirin decreases platelet aggregation and increases post-operative blood loss--a prospective, randomised, placebo controlled, double-blind clinical trial in 100 patients with chronic stable angina.
Topics: Aspirin; Blood Coagulation Tests; Blood Loss, Surgical; Blood Transfusion; Coronary Artery Bypass; C | 1994 |
Effect of various antithrombotic regimens (aspirin, aspirin plus dipyridamole, anticoagulants) on the functional status of patients and grafts one year after coronary artery bypass grafting.
Topics: Acenocoumarol; Adult; Aged; Anticoagulants; Aspirin; Coronary Artery Bypass; Coronary Circulation; C | 1994 |
Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Double-Blind Method; | 1994 |
Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Ne
Topics: Acenocoumarol; Administration, Oral; Aged; Aspirin; Coronary Artery Bypass; Dipyridamole; Drug Thera | 1993 |
Long-term graft patency (3 years) after coronary artery surgery. Effects of aspirin: results of a VA Cooperative study.
Topics: Aspirin; Cardiac Catheterization; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; | 1994 |
Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting.
Topics: Adolescent; Adult; Aged; Aspirin; Coronary Artery Bypass; Dipyridamole; Double-Blind Method; Drug Th | 1994 |
Factors influencing 1-year patency of coronary artery saphenous vein grafts. Studio Indobufene nel Bypass Aortocoronarico (SINBA).
Topics: Aspirin; Coronary Angiography; Coronary Artery Bypass; Dipyridamole; Double-Blind Method; Female; Gr | 1993 |
[No advantage in the addition of dipyridamole or of oral anticoagulants in comparison to low-dose acetylsalicylic acid (50 mg per day) in the prevention of venous transplant occlusion following coronary bypass surgery].
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Occlusion, Vascular; Humans | 1993 |
[No advantage in the addition of dipyridamole or of oral anticoagulants in comparison to low-dose acetylsalicylic acid (50 mg per day) in the prevention of venous transplant occlusion following coronary bypass surgery].
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Humans | 1993 |
[No advantage in the addition of dipyridamole or of oral anticoagulants in comparison to low-dose acetylsalicylic acid (50mg per day) in the prevention of venous transplant occlusion following coronary bypass surgery].
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Humans | 1993 |
[No advantage in the addition of dipyridamole or of oral anticoagulants in comparison to low-dose acetylsalicylic acid (50 mg per day) in the prevention of venous transplant occlusion following coronary bypass surgery].
Topics: Aspirin; Coronary Artery Bypass; Dipyridamole; Drug Therapy, Combination; Graft Occlusion, Vascular; | 1993 |
[No advantage in the addition of dipyridamole to, or of oral anticoagulants in comparison to, a low dose of acetylsalicylic acid (50 mg per day) in the prevention of venous transplant stenosis following coronary bypass surgery].
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Humans | 1994 |
Placebo-controlled trial of enteric coated aspirin in coronary bypass graft patients. Effect on graft patency.
Topics: Aged; Aspirin; Coronary Artery Bypass; Dipyridamole; Double-Blind Method; Female; Follow-Up Studies; | 1993 |
[The effect of indobufen on aortocoronary bypass patency after 1 week and after 1 year].
Topics: Adult; Aged; Aspirin; Coronary Artery Bypass; Dipyridamole; Female; Graft Occlusion, Vascular; Human | 1993 |
Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aprotinin; Aspirin; Blood Loss, Surgical; Card | 1998 |
PTCA of degenerated vein grafts: experience of two periods (1992-93 and 1996-97) in 780 patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Coronary Artery Bypass; Coro | 1998 |
beta-Particle-emitting radioactive stent implantation. A safety and feasibility study.
Topics: Adult; Aged; Aspirin; Beta Particles; Brachytherapy; Coronary Angiography; Coronary Disease; Feasibi | 1999 |
Usefulness of cilostazol versus ticlopidine in coronary artery stenting.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Cilostazol; Coronary Angiograp | 1999 |
Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Aspirin; Female; Graft Occlusion, Vascula | 2000 |
Plasma levels of C-reactive protein after coronary stent implantation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Coronary An | 2000 |
A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Chemotherapy, Adju | 2000 |
Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study).
Topics: Anticoagulants; Aspirin; Drug Administration Routes; Drug Delivery Systems; Enoxaparin; Female; Foll | 2001 |
Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Female | 2001 |
The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment.
Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Artery Bypass; Coronary Disease; Dose-Response Relati | 2001 |
The effect of anticoagulation therapy and graft selection on the ischemic consequences of femoropopliteal bypass graft occlusion: results from a multicenter randomized clinical trial.
Topics: Aged; Amputation, Surgical; Anticoagulants; Aspirin; Boston; Femoral Vein; Fibrinolytic Agents; Foll | 2002 |
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation: 1 and 6-month follow-up.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Stenosis; Drug Therapy, C | 2001 |
Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study.
Topics: Aged; Aprotinin; Aspartate Aminotransferases; Aspirin; Blood Loss, Surgical; Blood Transfusion; Ches | 1992 |
Efficacy and safety of anticoagulant therapy started pre-operatively in preventing coronary vein graft occlusion.
Topics: Aspirin; Cardiac Catheterization; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Drug Thera | 1992 |
The role of dipyridamole in addition to low dose aspirin in the prevention of occlusion of coronary artery bypass grafts.
Topics: Aged; Aspirin; Cardiac Catheterization; Cineangiography; Coronary Artery Bypass; Dipyridamole; Drug | 1992 |
[Experiences with adjuvant prostaglandin therapy in vascular surgery interventions].
Topics: Alprostadil; Arteriovenous Shunt, Surgical; Aspirin; Graft Occlusion, Vascular; Heparin; Humans; Isc | 1991 |
[Anticoagulant or antiplatelet aggregation treatment after aortocoronary bypass].
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Occlusion, Vascular; Humans; Me | 1991 |
PTFE or HUV for femoro-popliteal bypass: a multi-centre trial.
Topics: Arterial Occlusive Diseases; Aspirin; Bioprosthesis; Blood Vessel Prosthesis; Combined Modality Ther | 1991 |
A linear model suitable for assessing graft patency in controlled clinical trials. SINBA Group.
Topics: Anastomosis, Surgical; Angiography; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Dipyr | 1990 |
Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial.
Topics: Aspirin; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Femoral Artery; Follow-Up Stu | 1991 |
Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study.
Topics: Angiography; Aspirin; Blood Transfusion; Coronary Artery Bypass; Graft Occlusion, Vascular; Hemorrha | 1991 |
[Permeability of aortocoronary bypass after 6 months. A multicenter French study].
Topics: Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Dipyridamole; Female; Follow-Up | 1991 |
Prevention of aortocoronary vein bypass graft occlusion: which antithrombotic treatment and for how long?
Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Double-Blind Method; Dru | 1990 |
Does low-dose aspirin prevent aortocoronary vein bypass graft occlusion? The Spanish Group for Aortocoronary Bypass Follow-up (GESIC Study).
Topics: Aged; Aspirin; Coronary Artery Bypass; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; | 1990 |
Effect of dipyridamole and aspirin on vein graft patency after coronary bypass operations.
Topics: Aspirin; Coronary Artery Bypass; Dipyridamole; Drug Therapy, Combination; Graft Occlusion, Vascular; | 1990 |
Increased plasma beta-thromboglobulin in patients with coronary artery vein graft occlusion: response to low dose aspirin.
Topics: Adult; Aged; Angiography; Aspirin; beta-Thromboglobulin; Coronary Artery Bypass; Double-Blind Method | 1990 |
Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Grupo Español para el Seguimiento del Injerto Coronario (GESIC)
Topics: Aged; Aspirin; Coronary Artery Bypass; Dipyridamole; Drug Combinations; Graft Occlusion, Vascular; H | 1990 |
The effect of ibustrin on early aortocoronary bypass patency.
Topics: Angiography, Digital Subtraction; Aspirin; Coronary Angiography; Coronary Artery Bypass; Coronary Di | 1990 |
Internal mammary artery and saphenous vein graft patency. Effects of aspirin.
Topics: Aspirin; Coronary Angiography; Coronary Artery Bypass; Dipyridamole; Double-Blind Method; Graft Occl | 1990 |
Low-dose aspirin versus anticoagulants for prevention of coronary graft occlusion.
Topics: Aspirin; Coronary Artery Bypass; Female; Graft Occlusion, Vascular; Heparin; Humans; Male; Middle Ag | 1990 |
Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy.
Topics: Aspirin; Blood Transfusion; Coronary Artery Bypass; Dipyridamole; Double-Blind Method; Graft Occlusi | 1990 |
Pharmacologic prevention of graft occlusion.
Topics: Animals; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Clinical Trials as Topic; Cyclic AMP; De | 1985 |
Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion.
Topics: 4-Hydroxycoumarins; Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary | 1989 |
Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study.
Topics: Aspirin; Coronary Artery Bypass; Dipyridamole; Double-Blind Method; Graft Occlusion, Vascular; Human | 1989 |
Platelet-inhibitor drugs before and after coronary artery bypass surgery and coronary angioplasty: the basis of their use, data from animal studies, clinical trial data, and current recommendations.
Topics: Angioplasty, Balloon; Animals; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Coronar | 1986 |
Long term clinical outcome of coronary surgery and assessment of the benefit obtained with postoperative aspirin and dipyridamole.
Topics: Angina Pectoris; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamole; Follow-Up | 1988 |
[Naftidrofuryl in patients with prosthetic femoral-popliteal bypass].
Topics: Adult; Aged; Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Female; Femoral Artery; Fur | 1988 |
Platelet-inhibitory therapy in reconstructive arterial surgery.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamole; Double-Bli | 1985 |
Usefulness of aspirin for coronary artery disease.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Graft Occ | 1988 |
[Anticoagulants vs. low-dose aggregation inhibitors in the prevention of perioperative occlusion of aortocoronary bypass grafts. Preliminary results of a prospective randomized study].
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Occlusion, Vascular; Humans; Pl | 1987 |
Failure of combined acetylsalicylic acid and dipyridamole to prevent occlusion of aortocoronary venous bypass graft.
Topics: Aspirin; Coronary Angiography; Coronary Artery Bypass; Dipyridamole; Drug Combinations; Graft Occlus | 1987 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
Role of platelets and platelet inhibitors in aortocoronary artery vein-graft disease.
Topics: Animals; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamole; D | 1986 |
The role of aspirin in enhancing arterial graft patency.
Topics: Animals; Arteries; Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Dipyridamole; Drug Th | 1986 |
Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary A | 1986 |
Aspirin for the prevention of coronary thrombosis: current facts and perspectives.
Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disea | 1986 |
Improvement of aortocoronary bypass patency by antiplatelet drug administration. Preliminary communication.
Topics: Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamole; Follow-Up | 1986 |
Pathogenesis and prevention of aortocoronary bypass graft occlusion.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamole; Double-Blind Method; Drug T | 1986 |
Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery.
Topics: Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Di | 1985 |
Randomised placebo controlled trial of aspirin and dipyridamole in the prevention of coronary vein graft occlusion.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamole; Double-Blind M | 1985 |
Acetylsalicylic acid and dipyridamole improve the early patency of aorta-coronary bypass grafts. A double-blind, placebo-controlled, randomized trial.
Topics: Adult; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamole; Double-Blind Method; | 1985 |
A prospective randomized trial of aspirin in femoral popliteal and tibial bypass grafts.
Topics: Adult; Aged; Aneurysm; Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Female; Femur; Gr | 1985 |
Long-term fate of bypass grafts: the Coronary Artery Surgery Study (CASS) and Montreal Heart Institute experiences.
Topics: Animals; Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Dipyridamole; Follow-Up Studies; | 1985 |
168 other studies available for aspirin and Graft Occlusion, Vascular
| Article | Year |
|---|---|
Therapeutic-Dose Warfarin (International Normalized Ratio >1.6) Plus Aspirin Improved Long-Term Patency of Saphenous Vein Graft without Bleeding Complication.
Topics: Aspirin; Coronary Angiography; Graft Occlusion, Vascular; Humans; International Normalized Ratio; Sa | 2022 |
Dual Antiplatelet Therapy With Ticagrelor and Vein Graft Failure After Coronary Artery Bypass Graft Surgery-Reply.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Platelet Aggregation Inhibitors; Ticagre | 2022 |
Dual Antiplatelet Therapy With Ticagrelor and Vein Graft Failure After Coronary Artery Bypass Graft Surgery-Reply.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Platelet Aggregation Inhibitors; Ticagre | 2022 |
Dual Antiplatelet Therapy With Ticagrelor and Vein Graft Failure After Coronary Artery Bypass Graft Surgery-Reply.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Platelet Aggregation Inhibitors; Ticagre | 2022 |
Dual Antiplatelet Therapy With Ticagrelor and Vein Graft Failure After Coronary Artery Bypass Graft Surgery-Reply.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Platelet Aggregation Inhibitors; Ticagre | 2022 |
Dual Antiplatelet Therapy With Ticagrelor and Vein Graft Failure After Coronary Artery Bypass Graft Surgery.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Platelet Aggregation Inhibitors; Ticagre | 2022 |
Dual Antiplatelet Therapy With Ticagrelor and Vein Graft Failure After Coronary Artery Bypass Graft Surgery.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Platelet Aggregation Inhibitors; Ticagre | 2022 |
Dual Antiplatelet Therapy With Ticagrelor and Vein Graft Failure After Coronary Artery Bypass Graft Surgery.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Platelet Aggregation Inhibitors; Ticagre | 2022 |
Dual Antiplatelet Therapy With Ticagrelor and Vein Graft Failure After Coronary Artery Bypass Graft Surgery.
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Platelet Aggregation Inhibitors; Ticagre | 2022 |
Early asymptomatic graft failure in coronary artery bypass grafting: a study based on computed tomography angiography analysis.
Topics: Aspirin; Clopidogrel; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; | 2023 |
Long-Term Efficacy of Extended Dual Antiplatelet Therapy After Left Main Coronary Artery Bifurcation Stenting.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug-Eluting | 2020 |
Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopi | 2020 |
Diffuse saphenous vein graft thrombosis: resolution after one month of apixaban and dual antiplatelet therapy.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Graft Occlusion, Vascular; | 2020 |
Effect of Rivaroxaban and Clopidogrel Combination Therapy on In-Stent Responses After Everolimus-Eluting Stent Implantation in a Porcine Coronary Model.
Topics: Animals; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Vessels; Drug Therapy, Combination; Drug- | 2022 |
Dual Antiplatelet Therapy Duration After Venous Sinus Stenting for Idiopathic Intracranial Hypertension and Stent Survival-Is Longer Necessarily Better? A Meta-Regression.
Topics: Adult; Aspirin; Central Venous Pressure; Clopidogrel; Drug Therapy, Combination; Female; Graft Occlu | 2021 |
Triflusal in Patients With Aspirin Hypersensitivity Treated With Coronary Stent Implantation.
Topics: Aged; Aspirin; Drug Hypersensitivity; Female; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans | 2018 |
Preventing graft restenosis after coronary artery bypass grafting with tissue-type plasminogen activator.
Topics: Aged; Aspirin; Blood Coagulation; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Female; | 2017 |
Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study).
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2017 |
Effects of aspirin resistance and mean platelet volume on vascular access failure in hemodialysis patients.
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Blood Vessel Prosthesis Implantation; Drug Resistance; | 2019 |
Transient in-stent stenosis at mid-term angiographic follow-up in patients treated with SILK flow diverter stents: incidence, clinical significance and long-term follow-up.
Topics: Adult; Aged; Angiography, Digital Subtraction; Aspirin; Cerebral Angiography; Female; Follow-Up Stud | 2019 |
Preventing arteriovenous shunt failure in hemodialysis patients: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arteriovenous Shunt, Surgical; Aspirin; Aspirin, Dip | 2019 |
Impact of Point-of-Care Platelet Function Testing Among Patients With and Without Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Aged; Aspirin; Case-Control Studies; Clopidogrel; Drug-Eluting Stents; Fema | 2019 |
Antithrombotic Therapy Following CABG: For the Patient, Not the Bypass Graft.
Topics: Aspirin; Coronary Artery Bypass; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans; Rivaroxaban | 2019 |
Dual platelet antiaggregation therapy after myocardial revascularization surgery.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Graft Occlusion, Vascular; Hu | 2019 |
Thromboprophylaxis strategies for children with single-ventricle circulations (superior or total cavo-pulmonary connections) after stent implantation.
Topics: Anticoagulants; Aspirin; Child; Child, Preschool; Female; Fibrinolytic Agents; Fontan Procedure; Gra | 2019 |
Aspirin usage is associated with improved prosthetic infrainguinal bypass graft patency.
Topics: Amputation, Surgical; Aspirin; Blood Vessel Prosthesis Implantation; Comorbidity; Critical Illness; | 2014 |
Thrombotic occlusion of extracardiac conduit 4 months after Fontan surgery.
Topics: Aspirin; Child, Preschool; Drug Substitution; Drug Therapy, Combination; Fibrinolytic Agents; Fontan | 2013 |
Dual antiplatelet therapy after coronary artery bypass grafting: does off/on-pump play a role?
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Humans; Vascular Patency | 2014 |
Effects of eicosapentaenoic acid on platelet function in patients taking long-term aspirin following coronary stent implantation.
Topics: Administration, Oral; Aspirin; Blood Platelets; Coronary Artery Disease; Dose-Response Relationship, | 2014 |
An atypical presentation of an extremely late stent thrombosis after more than 7 years (2634 days) of DES implantation in a patient without obvious risk factors on regular dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elu | 2014 |
Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy.
Topics: Absorbable Implants; Adenosine; Adult; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusio | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; | 2014 |
Preoperative continuation of aspirin therapy may improve perioperative saphenous venous graft patency after off-pump coronary artery bypass grafting.
Topics: Aspirin; Cohort Studies; Coronary Artery Bypass, Off-Pump; Female; Graft Occlusion, Vascular; Humans | 2015 |
Invited commentary.
Topics: Aspirin; Coronary Artery Bypass, Off-Pump; Female; Graft Occlusion, Vascular; Humans; Male; Platelet | 2015 |
Angiographic and clinical results of everolimus-eluting stent utilization in saphenous vein graft lesions (ARES).
Topics: Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon; Aspirin; Clopidogrel; Coronary Artery By | 2015 |
Effectiveness of prolonged clopidogrel-based dual antiplatelet therapy after drug-eluting stent implantation: Evidence-based meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug Combinations; Dr | 2015 |
Cilostazol, Not Aspirin, Prevents Stenosis of Bioresorbable Vascular Grafts in a Venous Model.
Topics: Absorbable Implants; Animals; Aspirin; Blood Vessel Prosthesis; Cell Proliferation; Cilostazol; Dise | 2015 |
In-Pipeline Stenosis: Incidence, Predictors, and Clinical Outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cerebral Angiography; Cohort Studies; Embolizat | 2015 |
Duration of dual antiplatelet therapy after coronary stenting.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Graft Occlusion, Vascular; Humans; Plat | 2016 |
High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; F | 2016 |
Consistent aspirin use associated with improved arteriovenous fistula survival among incident hemodialysis patients in the dialysis outcomes and practice patterns study.
Topics: Aged; Arteriovenous Shunt, Surgical; Aspirin; Australia; Europe; Female; Gastrointestinal Hemorrhage | 2008 |
Aspirin resistance an underestimated risk in patients with drug-eluting stents?
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug-Eluting Stents; Graft Occlusion | 2008 |
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Thromb | 2009 |
Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents.
Topics: Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; | 2009 |
Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Resistance; Female; Follow-Up Studies; France; Graft Oc | 2009 |
Spontaneous recanalization of a completely occluded saphenous vein graft two months following acute myocardial infarction with persistent one year patency.
Topics: Aged; Aspirin; Coronary Artery Bypass; Drug-Eluting Stents; Fibrinolytic Agents; Graft Occlusion, Va | 2009 |
A very late stent thrombosis in a patient with diabetes: a call for lifelong dual anti-platelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Follow-Up Studies; Graft Occlusio | 2009 |
Antiplatelet therapy and vascular-access patency.
Topics: Aspirin; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; Graft Occlusion, Vasc | 2009 |
Invited commentary.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Graft Occlusion, Vascular; Graft Survival; Hum | 2009 |
Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Body Mass Index; Clopidogrel; Coro | 2009 |
Aspirin resistance after CABG.
Topics: Aged; Aspirin; Biomarkers; Blood Urea Nitrogen; C-Reactive Protein; Coronary Artery Bypass; Coronary | 2009 |
Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis.
Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Thrombosis; Drug Resistan | 2009 |
Dipyridamole plus aspirin and hemodialysis graft patency.
Topics: Aspirin; Blood Vessel Prosthesis; Dipyridamole; Drug Therapy, Combination; Graft Occlusion, Vascular | 2009 |
Dipyridamole plus aspirin and hemodialysis graft patency.
Topics: Aspirin; Blood Vessel Prosthesis; Dipyridamole; Drug Therapy, Combination; General Surgery; Graft Oc | 2009 |
Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disea | 2010 |
Perioperative management of the patient with a coronary stent.
Topics: Algorithms; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stent | 2010 |
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Vessel Prosthesi | 2010 |
Genetic variability in response to clopidogrel therapy: clinical implications.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2 | 2010 |
Invited commentary.
Topics: Acenocoumarol; Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Occlusion, Vascu | 2010 |
Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study.
Topics: Angioplasty; Aspirin; Calcinosis; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coro | 2011 |
Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Female; Follow-Up Studies; Graft Occlus | 2011 |
Exploring mechanisms of graft occlusion toward improved outcomes in coronary artery bypass graft surgery.
Topics: Aspirin; Coronary Angiography; Coronary Artery Bypass; Graft Occlusion, Vascular; Humans; Platelet A | 2011 |
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin | 2011 |
Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the preoperative aspirin and postoperative antiplatelets in coronary artery bypass grafting surgery.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Drug Therapy, Combination; Graft | 2011 |
Regarding "results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial".
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Drug Therapy, Combination; Graft Occlusi | 2011 |
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Graft Occlusion, Vascular; Hemor | 2011 |
Letter by Gasparovic et al regarding article, "Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial".
Topics: Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Disease; Dr | 2011 |
Letter by Bisdas et al regarding article, "Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial".
Topics: Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary | 2011 |
[Role of low-dose acetylsalicylic acid in comprehensive postoperative treatment of patients with lower-limb chronic arterial insufficiency].
Topics: Aspirin; Blood Coagulation; Blood Viscosity; Femoral Artery; Graft Occlusion, Vascular; Humans; Lowe | 2011 |
Assessment of platelet function by whole blood impedance aggregometry in coronary artery bypass grafting patients on acetylsalicylic acid treatment may prompt a switch to dual antiplatelet therapy.
Topics: Adult; Aspirin; Blood Platelets; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Comb | 2013 |
Occlusion of modified Blalock-Taussig shunt after clopidogrel cessation.
Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Clopidogrel; Fatal Outcome; Graft Occlusion, Vas | 2012 |
Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Resistance; | 2012 |
Utility of VasoCT in the treatment of intracranial aneurysm with flow-diverter stents.
Topics: Adult; Aged; Angiography, Digital Subtraction; Angioplasty, Balloon; Aspirin; Catheterization; Cereb | 2012 |
Aspirin sensitivity and coronary artery disease: implications for the practicing cardiologist.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Asthma; Chronic Disease; Coronary Artery Disease; Cyclooxyg | 2012 |
Oral everolimus inhibits in-stent neointimal growth.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Vessel Prosth | 2002 |
Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anticoagul | 2002 |
The use of the X-Sizer transluminal extraction catheter as an adjunct to stenting of occluded saphenous vein grafts.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Catheters, I | 2003 |
The efficacy of aspirin in patients undergoing infra-inguinal bypass and identification of high risk patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Graft Occlusion, Vasc | 2003 |
Beta brachytherapy of an old degenerated saphenous vein graft with occlusive in-stent restenosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Blood Vessel Prosthesis; Brachytherap | 2003 |
Regarding "regarding 'Veterans Affairs (VA) Cooperative Study #362'".
Topics: Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Chemoprevention; Clinical Trials as T | 2004 |
Resistance to antiplatelet drugs: is it real or relevant?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Brachytherapy; Clopid | 2004 |
Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: need to assess aspirin resistance?
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Brachytherapy; | 2004 |
Thrombosis and neointima formation in vein grafts are inhibited by locally applied aspirin through endothelial protection.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Arteries; Disease | 2004 |
[Cardiovascular pharmacology].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Fatty Acids, Omega-3; Fibrinolytic Agents; Graft Occl | 2004 |
National survey of coronary artery bypass grafting for coronary stenosis caused by Kawasaki disease in Japan.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Angioplasty, Balloon, Coronary; Aspirin; Ch | 2004 |
Late saphenous vein graft occlusion in patients with coronary bypass: possible role of aspirin resistance.
Topics: Aged; Aspirin; Case-Control Studies; Collagen; Coronary Artery Bypass; Drug Resistance; Epinephrine; | 2005 |
Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis.
Topics: Aged; Angina Pectoris; Aspirin; Coronary Artery Disease; Female; Fibrinolytic Agents; Graft Occlusio | 2005 |
Hypercoagulability affecting early vein graft patency does not exist after off-pump coronary artery bypass.
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Bypass, Off-Pump; Female; Graft Occlusion, Vascula | 2005 |
Feasibility trial of carotid stenting with and without an embolus protection device.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Commo | 2005 |
Idiopathic spontaneous coronary artery dissection and drug-eluting stents.
Topics: Adult; Aortic Dissection; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary Angiography; Female; Gra | 2006 |
Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial.
Topics: Algorithms; Arteriovenous Shunt, Surgical; Aspirin; Aspirin, Dipyridamole Drug Combination; Delayed- | 2005 |
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Clopidogrel; Drug Therapy, Combination; Graft Occlusion, Vas | 2005 |
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Clopidogrel; Drug Therapy, Combination; Graft Occlusion, Vas | 2005 |
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Clopidogrel; Drug Therapy, Combination; Graft Occlusion, Vas | 2005 |
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Clopidogrel; Drug Therapy, Combination; Graft Occlusion, Vas | 2005 |
Radial artery angiographic string sign: clinical consequences and the role of pharmacologic therapy.
Topics: Adrenergic alpha-Agonists; Anticoagulants; Aspirin; Blood Flow Velocity; Calcium Channel Blockers; C | 2006 |
Images in cardiology. Unexpected response of saphenous vein graft occlusion to antiplatelet drugs.
Topics: Aged; Aspirin; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Platelet Aggregation Inhibitors | 2006 |
Carotid stent failure: results of surgical rescue.
Topics: Aged; Angioplasty; Aspirin; Carotid Artery Diseases; Endarterectomy, Carotid; Female; Graft Occlusio | 2007 |
What is the optimal management for preventing saphenous vein graft diseases?: early results of intravascular angioscopic assessment.
Topics: Aged; Aged, 80 and over; Angioscopy; Anticoagulants; Aspirin; Coronary Artery Bypass; Graft Occlusio | 2007 |
Factitious anticoagulant-resistance as a cause of recurrent arterial bypass graft occlusions.
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Co | 2007 |
Very late coronary stent graft thrombosis after aspirin cessation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; Fibrinolytic Agents; Graft Occlusion, | 2007 |
Nitric oxide-donating aspirin (NCX 4016) inhibits neointimal thickening in a pig model of saphenous vein-carotid artery interposition grafting: a comparison with aspirin and morpholinosydnonimine (SIN-1).
Topics: Administration, Oral; Analysis of Variance; Anastomosis, Surgical; Animals; Aspirin; Carotid Arterie | 2007 |
Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Coated Materials, Biocompatible; C | 2008 |
Pharmacological prophylaxis against postoperative graft occlusion after peripheral vascular surgery: a world-wide survey.
Topics: Anticoagulants; Aspirin; Data Collection; Dipyridamole; Drug Utilization; Graft Occlusion, Vascular; | 1995 |
[Stent after-care: new approaches to coagulation inhibiting therapy].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation Tests; Coronary Disease; | 1995 |
Pulse-spray pharmacomechanical thrombolysis of thrombosed hemodialysis access grafts: long-term experience and comparison of original and current techniques.
Topics: Anastomosis, Surgical; Angioplasty, Balloon; Aspirin; Blood Vessel Prosthesis; Catheterization; Graf | 1995 |
The antithrombotic effects of ticlopidine and aspirin in a microvascular thrombogenic model.
Topics: Administration, Oral; Animals; Aspirin; Femoral Artery; Graft Occlusion, Vascular; Male; Microsurger | 1995 |
Low-molecular-weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting.
Topics: Anastomosis, Surgical; Aspirin; Dipyridamole; Drug Combinations; Femoral Artery; Graft Occlusion, Va | 1994 |
Omission of aspirin in patients following coronary artery bypass graft surgery.
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Drug Administration Schedule; Follow-Up Studies; Gr | 1994 |
Is this the end of the aspirin and vein graft story?
Topics: Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; Humans; Postoperative Complications; Tim | 1994 |
Prevention of graft occlusion by aspirin, dipyridamole, and oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Drug Therapy, C | 1993 |
Prevention of graft occlusion by aspirin, dipyridamole, and oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Artery Bypass; Data Interpretation, Statisti | 1993 |
[No advantage in the addition of dipyridamole to, or of oral anticoagulants in comparison to, a low-dose acetylsalicylic acid (50 mg per day) in the prevention of venous transplant stenosis following coronary bypass surgery].
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Occlusion, Vascular; Humans | 1994 |
The effect of platelet inhibitory therapy on graft thromboresistance.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Dogs; Drug Th | 1993 |
Occluded peripheral arteries and bypass grafts: lytic stagnation as an end point for pulse-spray pharmacomechanical thrombolysis.
Topics: Adult; Aged; Aspirin; Catheterization; Female; Graft Occlusion, Vascular; Humans; Leg; Male; Middle | 1993 |
Patency and morphology of fibrous polyurethane vascular prostheses implanted in the femoral artery of dogs after seeding with subcultivated endothelial cells.
Topics: Anastomosis, Surgical; Animals; Aspirin; Blood Vessel Prosthesis; Cells, Cultured; Dipyridamole; Dog | 1993 |
Platelet aggregometry can accurately predict failure of externally supported knitted Dacron femoropopliteal bypass grafts.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Amputation, Surgical; Anastomosis, Surgical; | 1993 |
The effect of platelet inhibitory therapy on prosthetic graft maturation.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Dogs; Drug Therapy, Combination; Female; Fe | 1993 |
Pharmacologic modulation of intimal hyperplasia in canine vein interposition grafts.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Carotid Arteries; Cilazapril; Cyclosporine; Dogs; Female; | 1993 |
Aspirin enhances platelet-derived growth factor-induced vascular smooth muscle cell proliferation.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Aorta; Arachidonate 12-Lipoxygenase; Arachidonic Acids; | 1997 |
Thromboxane A2 receptor density increases during chronic exposure to thromboxane A2 receptor antagonists after porcine carotid bypass.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Bridged Bicyclo Compounds, Heterocyclic; Carotid Arteries | 1997 |
Carotid-subclavian bypass for subclavian artery revascularization: long-term follow-up and effect of antiplatelet therapy.
Topics: Adult; Aged; Angiography; Anticoagulants; Arm; Arterial Occlusive Diseases; Aspirin; Blood Vessel Pr | 1998 |
Antiplatelet therapy and patency of saphenous-vein bypass grafts in the legs.
Topics: Aspirin; Graft Occlusion, Vascular; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhib | 1998 |
Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgery: results of a combined analysis.
Topics: Aspirin; Coronary Artery Bypass; Cyclooxygenase Inhibitors; Dipyridamole; Drug Therapy, Combination; | 1998 |
Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis.
Topics: Animals; Arteriovenous Shunt, Surgical; Aspirin; Bleeding Time; Blood Platelets; Clopidogrel; Corona | 1998 |
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts.
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Fibrinolytic Agents; Graft Occlusion, | 1998 |
Spontaneous occlusion of systemic-to-pulmonary arterial shunts.
Topics: Anticoagulants; Aspirin; Child; Fibrinolytic Agents; Graft Occlusion, Vascular; Heparin; Humans; Hyp | 1999 |
Reduced frequency of occlusion of aorto-pulmonary shunts in infants receiving aspirin.
Topics: Aorta; Arteriovenous Shunt, Surgical; Aspirin; Case-Control Studies; Female; Graft Occlusion, Vascul | 1999 |
Antithrombotic drug therapy after infrainguinal vascular surgery.
Topics: Administration, Oral; Anticoagulants; Aspirin; Graft Occlusion, Vascular; Humans; Leg; Platelet Aggr | 2000 |
Saphenous vein graft disease treated with the Wiktor Hepamed stent: procedural outcome, in-hospital complications and six-month angiographic follow-up.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Female; Fibrinolytic Agents; Follow-Up | 2000 |
Interpretation of Dutch BOA trial. Dutch Bypass Oral anticoagulants or Aspirin study group.
Topics: Administration, Oral; Anticoagulants; Aspirin; Graft Occlusion, Vascular; Humans; Platelet Aggregati | 2000 |
Short-term outcome of stent implantation in saphenous vein grafts: predictors of distal embolization and restenosis.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Combined Modality Therapy; Comorbidity; Coronary Ang | 2001 |
Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (the Dutch Bypass Oral anticoagulants or Aspirin study). Lancet 2000; 355: 346-51.
Topics: Administration, Oral; Anticoagulants; Aspirin; Graft Occlusion, Vascular; Humans; Leg; Platelet Aggr | 2001 |
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibod | 2001 |
Prevention of venous graft sclerosis with clopidogrel and aspirin combined with a mesh tubing in a dog model of arteriovenous bypass grafting.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Carotid Artery, Common; Clopidogrel; Dogs; Drug Therapy, | 2001 |
[Prevention of occlusions after infra-inguinal bypass surgery with oral anticoagulants or acetylsalicylic acid; a randomized comparison].
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Artery Bypass; Graft Occlusion, Vascular; He | 2001 |
Aspirin versus clopidogrel for synthetic graft patency after peripheral arterial bypass grafting.
Topics: Arteries; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Pe | 2001 |
Effect of aspirin on intimal proliferation and tissue cholesterol in long-term experimental bypass grafts.
Topics: Animals; Aspirin; Cell Division; Cholesterol; Coronary Artery Bypass; Dogs; Endothelium, Vascular; G | 1992 |
Aspirin and dipyridamole in the prevention of coronary disease and coronary artery bypass graft occlusion.
Topics: Aspirin; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Graft Occlusion, Vascular; Humans | 1992 |
Starting aspirin therapy after operation.
Topics: Aspirin; Coronary Artery Bypass; Coronary Disease; Graft Occlusion, Vascular; Humans; Postoperative | 1992 |
Myocardial infarction in patients with previous bypass surgery.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Angiography; Coronary Disease; Diltiazem; Electrocard | 1991 |
[Arterioarterial shunt coated with collagen. A model of acute arterial thrombosis for testing antithrombotic agents in rats].
Topics: Animals; Aspirin; Carotid Arteries; Clopidogrel; Collagen; Disease Models, Animal; Fistula; Graft Oc | 1991 |
Coronary bypasses 10 years on.
Topics: Aspirin; Coronary Artery Bypass; Coronary Disease; Female; Graft Occlusion, Vascular; Humans; Male; | 1991 |
Factors affecting the patency of small-caliber prostheses: Observations in a suitable canine model.
Topics: Anastomosis, Surgical; Animals; Aspirin; Blood Vessel Prosthesis; Carotid Arteries; Dogs; Female; Fe | 1991 |
Effect of aspirin on intimal hyperplasia and cholesterol uptake in experimental bypass grafts.
Topics: Animals; Arteriosclerosis; Aspirin; Cell Division; Cholesterol; Dogs; Graft Occlusion, Vascular; Hyp | 1991 |
The effect of thromboxane receptor blockade versus thromboxane synthase inhibition on canine arterial graft patency.
Topics: Animals; Aspirin; Benzofurans; Bridged Bicyclo Compounds, Heterocyclic; Dipyridamole; Dogs; Fatty Ac | 1990 |
Occlusion after coronary revascularization.
Topics: Aspirin; Blood Platelets; Graft Occlusion, Vascular; Humans; Myocardial Revascularization | 1990 |
Antiplatelet therapy to prevent coronary artery bypass graft occlusion.
Topics: Aspirin; Coronary Artery Bypass; Dipyridamole; Drug Combinations; Graft Occlusion, Vascular; Humans; | 1990 |
A new primate model for the study of intravenous thrombotic potential and its modification.
Topics: Animals; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Dextrans; Graft Occlusion, Vascular; Hep | 1988 |
Dipyridamole.
Topics: Aspirin; Coronary Artery Bypass; Dipyridamole; Drug Therapy, Combination; Graft Occlusion, Vascular; | 1989 |
Mechanisms responsible for inhibition of vein-graft arteriosclerosis by fish oil.
Topics: Animals; Arteriosclerosis; Aspirin; Carotid Arteries; Dogs; Drug Evaluation, Preclinical; Drug Thera | 1989 |
[Behavior of platelets and leukocytes on the luminal surface of small caliber prosthetic grafts].
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Aspirin; Blood Vessel Prosthesis; Cell Adhesion; Dogs; | 1988 |
Effects of antiplatelet agents in combination with endothelial cell seeding on small-diameter Dacron vascular graft performance in the canine carotid artery model.
Topics: Animals; Aspirin; Benzofurans; Blood Platelets; Blood Vessel Prosthesis; Carotid Arteries; Dipyridam | 1985 |
Reduction of indium-111 platelet deposition on Dacron vascular grafts in humans by aspirin plus dipyridamole.
Topics: Adult; Aged; Aspirin; Blood Platelets; Dipyridamole; Graft Occlusion, Vascular; Humans; Indium; Male | 1986 |
Antiplatelet therapy and vascular grafts. Studies in a baboon ex vivo shunt.
Topics: Animals; Aspirin; Bleeding Time; Blood Coagulation; Blood Platelets; Blood Vessel Prosthesis; Graft | 1986 |
[Reopening of long-segment occluded aortocoronary venous bypasses. Short- and long-term results].
Topics: Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Combined Modality Therapy; Coronary Angiogr | 1988 |
Beneficial effect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Dogs; Graft Occlusion, Vascular; Platelet Aggregation; Po | 1986 |
Vascular grafts in microvascular surgery. An experimental study.
Topics: Animals; Aorta, Abdominal; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Graft Occlusion, Vascu | 1988 |
The association of in vitro arachidonic acid responsiveness and plasma thromboxane levels with early platelet deposition on the luminal surface of small-diameter grafts.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Aspirin; Benzofurans; Blood Vessel Prosthesis; Dogs; G | 1988 |
Percutaneous transluminal angioplasty of stenotic deep vein arterial bypass grafts.
Topics: Aged; Angioplasty, Balloon; Aspirin; Female; Femoral Vein; Graft Occlusion, Vascular; Humans; Male; | 1985 |
Platelet-inhibitor therapy in cardiovascular disease. Effective defense against thromboembolism.
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Bioprosthesis; Blood Platelets; Coronary Disease; Dip | 1985 |
Patency rate of small caliber fibrous polyurethane vascular prostheses implanted in the dog carotid and femoral artery improved by use of acetylsalicylic acid and dipyridamol.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Carotid Arteries; Dipyridamole; Dogs; Female; Femoral Art | 1988 |
Effects of aspirin, dipyridamole, and cod liver oil on accelerated myointimal proliferation in canine veno-arterial allografts.
Topics: Animals; Aspirin; Cholesterol, Dietary; Cod Liver Oil; Dipyridamole; Dogs; Elastic Tissue; Endotheli | 1988 |
[Dipyridamole and low-dose aspirin in patients with aortocoronary bypass--comparison with anticoagulants].
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Drug Therapy, Combination; Graft Occl | 1988 |
Management of problems related to the occluded femoro-distal bypass.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Vessel Prosthesis; Femoral Artery; Graft Occlusion, Va | 1987 |
Prostacyclin production by internal mammary artery as a factor in coronary artery bypass grafts.
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Aspirin; Coronary Artery Bypass; Dinoprostone; Endothelium; Fema | 1986 |
[Role of platelet anti-aggregants in cardiovascular surgery].
Topics: Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Occlusion, Vascular; Humans; Platelet Aggregati | 1987 |
The effect of predetermined thrombotic potential of the recipient on small-caliber graft performance.
Topics: Animals; Aspirin; Blood Cell Count; Blood Vessel Prosthesis; Carotid Arteries; Dogs; Drug Therapy, C | 1986 |
Endothelial cell seeding improves 4 mm PTFE vascular graft performance in antiplatelet medicated dogs.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Dipyridamo | 1987 |
[Mode of action and clinical evaluation of platelet aggregation inhibitors].
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Graft Occlusion, Vascular; Humans; Ketanserin; Myo | 1987 |
The effects of aspirin, dipyridamole and warfarin in femorodistal reconstruction: long-term results.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis Obliterans; Arteriovenous Shunt, Surgical; Aspirin; | 1987 |
Effect of the cyclo-oxygenase inhibitor indobufen on platelet accumulation in prosthetic vascular grafts.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Disease Models, Animal; Dogs; Drug Evaluati | 1986 |
Ticlopidine versus aspirin and dipyridamole: influence on platelet deposition and three-month patency of polytetrafluoroethylene grafts.
Topics: Animals; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Dogs; Female; Femoral Arter | 1986 |
Platelet antagonists eliminate thromboembolic complications of small-diameter arterial prostheses.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Graft Occlusion, Vascular; Male; Platelet A | 1987 |
Adverse effects of high dose aspirin on platelet adhesion to experimental autogenous vein grafts.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Autoradiography; Carotid Arteries; Dipyridamole; Epo | 1985 |
Comparison of cod-liver oil and aspirin-dipyridamole for the prevention of intimal hyperplasia in autologous vein grafts.
Topics: Animals; Aspirin; Blood Platelets; Cod Liver Oil; Dietary Fats; Dipyridamole; Dogs; Drug Combination | 1986 |
Aspirin or dipyridamole individually prevent lipid accumulation in primate vein bypass grafts.
Topics: Animals; Apolipoproteins B; Arteriovenous Shunt, Surgical; Aspirin; Cholesterol; Dipyridamole; Drug | 1985 |